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The apelin-apelin receptor (APLNR) system is an important regulator of 
cardiovascular homeostasis both in health and disease. Principal actions of the 
apelin-APLNR system are positive inotropism, vasodilatation, diuresis and a 
potential anti-inflammatory role in vascular tissue.  
 
The significance of this system is highlighted in heart failure and pulmonary 
hypertension. Preclinical models of these diseases report downregulation of apelin-
APLNR, whilst knockout strains develop more severe phenotypes, more rapidly. 
Moreover treatment with exogenous apelin retards or prevents disease progression.  
 
In man plasma apelin concentrations are reduced in heart failure and vary with 
disease severity. Initial increases are reported in mild heart failure suggesting a 
compensatory role, but are depressed in severe heart failure. Limited data profile 
myocardial APLNR expression in heart failure and in keeping with plasma apelin 
concentrations, expression is reduced in severe heart failure.  
 
Of interest, the APLNR most closely resembles the angiotensin II type 1 receptor 
(AT1R), sharing similar tissue expression and sequence homology, but mediates 
opposing physiological actions. Furthermore, emerging preclinical data support 
receptor interactions between the APLNR and AT1R that modify their native 
signalling pathways. It is likely that the apelin-APLNR system serves to antagonise 
the renin-angiotensin system. Given the established role of angiotensin II, arguably 
the most important peptide in cardiovascular pathophysiology, any system 
influencing its actions merits further investigation.  
 
Current clinical studies are limited to 20 minutes infusions and understanding its 
cardiovascular effects requires more prolonged administration. There are concerns of 
tachyphylaxis and interaction with the renin-angiotensin-aldosterone system 
(RAAS), possibly reducing efficacy of APLNR agonism in clinical settings.  
 
In a series of randomised, blinded crossover clinical trials 60 healthy volunteers and 
20 patients with chronic stable heart failure were enrolled to assess the effects of 
(Pyr1)apelin-13 infusion at rest, during acute and subacute infusion, exercise and 
upregulation of the renin-angiotensin system. I have identified that APLNR agonism 
is unaffected by prevailing levels of angiotensin II activity in local vascular beds and 
systemic haemodynamic infusions. Furthermore, the efficacy of (Pyr1)apelin-13 is 
retained in healthy volunteers and patients with chronic stable heart failure during 
acute and subacute infusions. Finally, systemic (Pyr1)apelin-13 does not alter 
exercise performance in healthy individuals. 
 
My findings support a role in targeting the APLNR in chronic heart failure and 
predict that efficacy will be retained in chronic dosing. Future research directed at 
other patient groups with ventricular dysfunction is merited, in order to further 
characterise the utility of this system. These studies are encouraging; however, 
longer term studies may reveal effects beyond haemodynamic alterations and 
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examine the effects on cardiac fibrosis and endothelial function. A long acting 
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The apelin receptor (APLNR) and its ligand, apelin, constitute a relatively new 
peptidic system with an emerging and important physiological and 
pathophysiological role that is currently being defined (Figure 1.1). In vitro and 
preclinical models have suggested that the apelin-APLNR system plays an important 




















Figure 1.1.  Cardiovascular role of the apelin-APLNR system in health and disease. 
NO - nitric oxide; Ca++ - calcium ion; Ang II - angiotensin II; APLNR - apelin receptor; AP - alkaline 
phosphatase; T2DM - type 2 diabetes mellitus. 
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1.1 APELIN AND THE APELIN RECEPTOR 
 
The apelin receptor is a G protein-coupled receptor (GPCR), first identified in 1993 
[O'Dowd et al 1993]. It is expressed in a wide range of tissues, including the 
endothelium, myocardium [Hosoya et al 2000; Kleinz et al 2004; Kleinz et al 2005; 
Farkasfalvi et al 2007, Földes et al 2003]], adipose tissue [Hosoya et al 2000], brain 
[De Mota et al 2000; Medhurst et al 2003], renal (Hus Citheral et al 2008], gastro-
intestinal tract, spleen, adrenal glands, placenta [Medhurst et al 2003] and adipose 
tissues [Boucher et al 2005] (Table 1). The apelin receptor remained orphaned until 
1998, when its ligand apelin (APJ receptor Endogenous LigaNd)** was extracted 
from bovine stomach tissue [Tatemoto et al 1998]. It is unclear whether apelin acts 
on the APLNR in an autocrine, paracrine or hormonal manner, but most evidence 
supports a paracrine focus of action. 
 
 
**The APLNR has previous synonyms including AGRL1, APJ, APJR, and  












Table 1. Distribution of apelin and APLNR, with sub organ and functional unit data 
where possible.  
Tissue Apelin     APLNR 
Brain + + 
 Spinal cord ++ +++ 
 Thalamus + + 
 Hypothalamus + + 
 Pituitary + + 
 Cerebellum + + 
 Cerebrum + + 
Lung +++ +++ 
Heart + + 
 Left ventricle  + + 
 Right ventricle + + 
 Atria +++ +++ 




 Proximal convoluted tubule  + 
 Proximal straight tubule (cortex)  + 
 Proximal straight tubule (medulla)  + 
 Thick ascending limb (medulla)  + 
 Thick ascending limb (cortex)  + 
 Collecting duct (outer medulla)  + 
 Collecting duct (inner medulla)  + 
Placenta ++ +++ 
Liver - + 
Vasculature + + 
 Smooth muscle + + 
 Endothelium  + + 
Adrenal + + 
Spleen +++ ++ 
Skeletal muscle + + 
Intestine + + 
Stomach + + 
Adipocytes + + 
Pancreas + + 
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Apelin is synthesised as a 77 amino acid prepropeptide that is cleaved into a smaller 
biologically active fragments. The 36 amino acid peptide, which has the highest 
binding affinity for the APLNR however shorter isoforms are more potent 
[Kawamata et al 2001]. The prepropeptide contains a number paired basic amino 
acid sites that are targets for endopeptidases (Figure 1.2).  Formation of a 
pyroglutamate N terminus is a post-transcriptional modification that reduces enzyme 
degradation and therefore preserves activity [Garden et al 1999].  The 
pyroglutamated 13 amino acid, (Pyr1)apelin-13 is the most potent and most abundant 
in cardiac tissue [Maguire et al 2009]. Although the main source of plasma apelin is 
unclear, the cardiac atria [Földes et al 2003] are likely to be significant contributors.  
Tissue locations of apelin are summarised in table 1. 
 
The pathways of apelin metabolism and breakdown are currently obscure, but the 
mature 77 amino acid peptide contains a number of basic residues that are potential 
cleavage sites for peptidases. Presently, angiotensin-converting enzyme (ACE) II is 
the only enzyme known to break down the mature apelin peptide [Vickers et al 
2002]. Apelin has a brief half-life of under 5 minutes in man, and its cardiovascular 
actions are short-lived [Japp et al 2008]. 
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Apelin sythesis and  metabolism. Cleavage sites (black underline) in regions with arginine (red) and lysine 
(green) rich domains. A) Aplein-36. B) Apelin-17 C) Apelin-13. D) (Pyr1)apelin-13 
 
 
1.1.2 APLNR SIGNALING  
 
Intracellular signalling cascades are incompletely understood however the APLBR 
appears to promote signalling through more than one pathway. In Chinese Hamster 
ovary cells, apelin inhibits forskorlin stimulated cAMP production in a dose 
dependent fashion [Habata et al 1999], suggesting that APLNR signalling is coupled 
to Gαi protein. Moreover in cells treated with pertussis toxin, which selectively 
inhibits Gαi subunits, apelin mediated intracellular signalling is entirely prevented 
[Masri et all 2002]. Selective pharmacological inhibition of different α subunits 
identified that it is αi1 and αi2 subunits are coupled to APLNR. [Mesri et all 2006].  
 
However in perfused heart models, pertussis toxin only partially inhibits APLNR 
mediated positive inotropism [Szodoki et al 2002]. In this model inhibition of 
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phospholipase C and protein kinase C resulted in greatly reduced effects of APLNR 
stimulation [Szodoki et al 2002].  Phospholipase C is the major Gαq effector and 
hydrolyses phosphatidylinositol-4, 5- bisphosphate (PIP2), generating inositol-1, 4, 5-
trisphosphate (IP3) and diacylglycerol (DAG).  IP3 releases cytolsolic calcium stores, 
whilst DAG activates PKC.  Taken together these data suggest that the APLNR 
receptor can activate intracellular signalling though αi and αq subunits. 
 
 
1.2 CARDIOVASCULAR ACTIONS OF APELIN 
 
1.2.1  VASCULAR ACTIONS 
Apelin receptor stimulation predominantly results in vasodilatation, as demonstrated 
in ex vivo models of animal and human conduit arteries, resistance vessels and veins 
[Salcedo et al 2007; Zhong et al 2007b; Maguire et al 2009]. Accordingly, 
intravenous administration in rodents reduces mean arterial pressure [Lee et al 2000;  
Tatemoto et al 2001; Cheng et al 2003; Ishida et al 2004], systemic venous tone        
[Cheng et al 2003] and cardiac preload and afterload [Ashley et al 2005].         
Apelin-mediated vasodilatation is endothelium-dependent, since vasoconstriction 
occurs in endothelium-denuded vessels [Katugampola et al 2001; Maguire et al 
2009]. Furthermore, apelin promotes dose-dependent phosphorylation of myosin 
light chain protein in cultured vascular smooth muscle cells and aortic tissue, both 
lacking functional endothelium, thereby providing a potential mechanism of 
vasoconstriction [Hashimoto et al 2006; Wang et al 2008]. 
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Vasodilatation appears to be mediated through predominantly nitric oxide-dependent 
pathways: in vitro apelin increases nitric oxide synthase transcription [Jia et al 2007] 
and phosphorylation [Zhong et al 2007b], while in vivo apelin increases plasma 
nitrate and nitrite concentrations [Tatemoto et al 2001]. Furthermore, the inhibition 
of nitric oxides synthase markedly attenuates both depressor [Tatemoto et al 2001] 
and vasodilator [Japp et al 2008] responses. In human mammary arteries and 
saphenous veins, although not in mesenteric resistance vessels, apelin induces 
vasodilatation through prostacyclin-dependent pathways [Maguire et al 2009]. The 
vascular effects of apelin in clinical studies mirror those in animal models. Intra-
arterial infusion of apelin causes reproducible vasodilatation in human forearm 
circulation [Japp et al 2008]. In this model, vasodilatation to apelin is reduced by 
two-thirds in the presence of nitric oxide inhibition, but it is unaffected by 
prostacyclin inhibition [Japp et al 2008]. Apelin does not appear to exert in vivo 
vasomotor effects in human dorsal hand veins, but the effects on central capacitance 
vessels are yet to be studied. In addition to these two studies, data from our own 
group have demonstrated that apelin is also a coronary vasodilator and, when 
administered at systemic doses, reduces peripheral vascular resistance [Japp et al 
2010]. There are no data supporting a vasoconstrictor role for apelin in healthy 
volunteers or patients. However, given that preclinical studies have demonstrated a 
need for endothelium to mediate vasodilatation [Katugampola et al 2001], it is 






1.2.2  CARDIAC ACTIONS 
Apelin is the most potent endogenous inotropic described to date. In vitro, exogenous 
apelin increases contractility at subnanomolar concentrations in atrial strips   
[Maguire et al 2009] and whole rat hearts [Szokodi et al 2002], and it increases 
sarcomere shortening by 140% in isolated cardiomyocytes [Farkasfalvi et al 2007]. 
In healthy rodents, acute apelin infusion increases myocardial contractility, 
independent of its loading conditions [Ashley et al 2005] while, uniquely among 
current inotropic agents, chronic dosing causes a sustained increase in cardiac output, 
without inducing left ventricular hypertrophy [Ashley et al 2005]. 
 
Recent studies have shown that endogenous apelin-APLNR signalling makes an 
important contribution to maintaining cardiac function. Isolated ventricular myoctyes 
from both apelin- and APLNR-deficient mice have impaired sarcomeric function 
resulting in reduced myocyte contractility [Charo et al 2009]. Whilst apelin-deficient 
mice display normal or minimally impaired basal cardiac function, they demonstrate 
a marked reduction in exercise capacity and maximal oxygen consumption        
[Charo et al 2009]. Furthermore, these knockout rodents manifest progressive 
cardiac dysfunction from 6 months of age and develop severe heart failure when 
subjected to chronic pressure overload via surgical aortic banding [Kuba et al 2007]. 
Taken together, these data suggest a critical role for apelin-APLNR signalling in 




The inotropic actions of apelin are independent of angiotensin II, endothelin, 
catecholamines and nitric oxide release [Szokodi et al 2002]. Although data conflict 
to some extent, it appears that apelin acts predominantly through mechanisms other 
than by raising intracellular calcium concentrations (Figure 1.3).   
 
APNLR stimulation in the myocardium activates different pathways that are coupled 
to different Gα subunits. Through the Gαi subunit, phospholipase C is activated, 
which in turn generates IP3 leading to protein kinase C activation and increased the 
activity of sodium-hydrogen ion exchanger (Na+/H+ exchanger, NHE). [Szokodi et al 
2002]. In addition to activating NHE protein kinase C functions to activate myosin 
light chain kinase (MLCK), which promotes positive inotropism through increased 
phosphorylation of sarcomeric proteins. Additionally, through Gαq pathways, 
extracellular-regulated kinases 1 and 2 (ERK 1/2) is activated through MEK1, which 
also stimulates NHE. Stimulation of the NHE leads to intracellular alkalinisation and 
the sensitisation of cardiac myofilaments to intracellular calcium ions [Karmazyn et 
al 1999]. Accordingly, in isolated cardiomyocytes, apelin activates the NHE, thus 
increasing intracellular pH [Farkasfalvi et al 2007]. An additional effect of 
intracellular alkalisation is activation of the sodium-calcium exchange, which works 
in reverse to raise intracellular calcium. In these and other studies [Szokodi et al 
2002] of isolated cardiomyocytes, apelin had no effect on calcium ion transients. 
Furthermore, isolated cardiomyocytes from APLNR- and apelin-deficient patients 
with impaired cardiac function show no alteration in calcium ion transients [Charo et 
al 2009]. However, apelin causes a modest increase in the amplitude of the 
intracellular calcium ion transients in failing rat trabeculae [Dai et al 2006] and 
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isolated cardiomyocytes [Wang et al 2008], suggesting the possibility of an 
additional mechanism involving increased calcium sensitivity.  
 
Figure 1.3 Mechanisms of APLNR mediated inotropism. APLNR - apelin 
receptor; q - Gαq protein; i - Gαi protein; ERK 1/2 extracellular-regulated 
kinases 1 and 2;  PLC - Phospholipase C; SR - sacroplasmic reticulum; Ca++ - 
calcium; NHE - Na+/H+ exchanger; NCX - reverse Na+/Ca2+ exchanger; PIP2 - 
phosphatidylinositol 4,5-bisphosphate; IP3 - inositol 3,4,5 trisphosphate; DAG 
- diacylglycerol.; MLCK - myosin light chain kinase. 
 
1.2.3  EXERCISE PHYSIOLOGY 
There are limited data available assessing the contribution of the apelin-APLNR 
system to exercise physiology. One preclinical study has assessed resting myocardial 
function and exercise performance in apelin- or APLNR-deficient strains [Charo et 
al 2009]. Both of these knockout rodents had reduced exertion capacity compared to 









































during exercise is unclear, as is the effect of exogenous apelin during exercise 
assessment. However, it is most likely that APLNR agonism will be of benefit in 
disease with reduced circulating apelin concentrations. 
 
 
1.2.4  FLUID HOMEOSTASIS 
Apelin and the APLNR are present in the kidney and many areas of the brain. High 
concentrations are found in the supra-paraventricular nuclei and supra-optic nuclei 
[De Mota et al 2000]: regions involved in fluid homeostasis. Here, the synthesis and 
secretion of apelin appear to be regulated by vasopressin [Reaux-Le Goazigo et al 
2004]. In turn, intracerebral injection of apelin directly inhibits vasopressin release, 
leading to a 40% reduction in plasma vasopressin concentrations. In keeping with 
this notion, apelin has diuretic properties [De Mota et al 2004; Hus-Citharel et al 
2008] that appear to be aquaretic, with little or no apparent increase in sodium 
excretion [De Mota et al 2004]. In man, water loading results in elevated plasma 
apelin concentrations, while increased plasma osmolality causes plasma apelin 
concentration to fall; in each case there is a reciprocal change in vasopressin 
concentration [Azizi et al 2008]. Overall, these changes suggest that apelin may 







1.2.5  GLUCOSE METABOLISM 
Apelin is expressed in mouse and human adipose, and in vitro adipose tissue 
synthesises apelin [Boucher et al 2005]. Apelin expression tracks plasma insulin 
concentrations, with fasting reducing adipose expression, which returns to baseline 
through refeeding [Boucher et al 2005]. Exogenous apelin reduces the peak glucose 
concentration after glucose loading, by increasing glucose turnover                      
[Dray et al 2008] through insulin-dependent and independent pathways. Apelin-
deficient animal models have reduced insulin sensitivity, and this can be corrected by 
the administration of exogenous apelin [Yue et al 2010]. The effect of exogenous 
handling in man is currently unknown.  
 
 
1.3 THE APELIN-APLNR AND RENIN-ANGIOTENSIN SYSTEMS 
 
Among the G protein-coupled receptors, the APLNR displays the closest homology 
to angiotensin II type 1 receptor (AT1R) at around 50%, predominantly in the 
transmembrane domains. Furthermore, similar patterns of tissue expression are 
evident for both receptors [Ashley et al 2006]. Physiologically, the actions of the 
renin-angiotensin system and the apelin-APLNR system are antagonistic, with 
opposing actions on vascular tone [Gurzu et al 2006], blood pressure                    
[Ishida et al 2004], atherosclerosis [Chun et al 2008] and fluid homeostasis         
[Hus-Citharel et al 2008]. However, there are accumulating data to suggest direct 






The presence of the APLNR modifies the vascular actions of angiotensin II. 
Myography studies in arteries from diabetic mice, which have reduced APLNR 
expression, show increased angiotensin II constriction [Zhong et al 2007a]. In whole 
animals, rodents deficient in APLNR and AT1R exhibit elevated baseline mean 
arterial pressure, supporting the role of the APLNR opposing the renin-angiotensin 
system [Ishida et al 2004]. Furthermore, in these double knockout strains, 
exaggerated pressor responses to angiotensin II infusion imply that the presence of 
the APLNR modifies the potency of angiotensin II [Ishida et al 2004]. Cellular 
models have investigated the interaction between these two systems. Human 
embryonic kidney cells co-transfected with both the AT1R and APLNR have 
reduced downstream signalling from angiotensin II [Sun et al 2011]. In agreement 
with this finding, knockdown cellular models that reduce APLNR expression with 
small interfering ribonucleic acid (siRNA) exhibit exaggerated responses to 
angiotensin II [Chun et al 2008]. Therefore, in cellular, myography and whole 


































Figure 1.3.  Interaction between the apelin-APLNR and renin-angiotensin systems. 
APLNR - apelin receptor; AT1R - angiotensin II type 1 receptor; ATRA - all-trans retinoic acid.	
Signal transduction interaction 
Apelin binding to APLNR results in 
inhibition of downstream angiotensin 
II mediated transcription targets from 
the  AT1R 
APLNR 
Receptor interaction 
Angiotensin II binding to AT1R triggers 
“heterodimer” formation 
Angiotensin II Apelin 
Expression interaction 
Angiotensin II inhibits APLNR expression  
Pharmacological inhibition of AT1R expression is 
accompanied by increased APLNR receptor expression  




APLNR and AT1R can form heterodimers [Chun et al 2008; Sun et al 2011], which 
is proposed as a significant mechanism for the interaction between these two 
systems. The AT1R forms heterodimers with several G protein-coupled receptors in 
vitro [AbdAlla et al 2000; AbdAlla et al 2001; AbdAlla et al 2005]. Functionally, the 
APLNR-formed heterodimer inhibits downstream signalling from the AT1R, which 
is independent of apelin but promoted by angiotensin II [Chun et al 2008; Sun et al 
2011]. However, heterodimer formation has, as yet, only been observed in vitro. 
Furthermore, studies have been unable to recreate AT1R formation in a range of 
models [Hansen et al 2009], suggesting that this may be a complex interaction 
requiring specific conditions, and it is unclear if these conditions are recreated in 
man. It is possible that heterodimers may not form in vivo, and this behaviour does 
not reflect native tissues or has little contribution to tissue metabolism. Additionally 
there are vast numbers of G protein-coupled receptors, which may be constantly 
forming dynamic receptor complexes; dissecting the contribution of one interaction 
in native tissues may be challenging. 
 
The contribution of apelin in the modification of AT1R signalling produces varying 
results. The inactive APLNR has been reported as key regarding its antagonist role, 
with apelin preventing heterodimer formation and promoting angiotensin II signals 
[Sun et al 2011]. However, Chun et al [2008] reported reduced AT1R signalling in 
the presence of activated APLNR. Whilst these are similar models, it is possible that 
alterations to receptor expression and density may exist and explain why differing 
results are reported. 
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Counter regulation of gene expression  
In addition to cell signalling and receptor interaction, these systems interact at the 
level of gene expression in vitro. In cellular models of maturing adipocytes, blockade 
of angiotensin II increases apelin expression and peptide secretion [Hung et al 2010]. 
Whole animal models are in keeping with this observation and administration of 
angiotensin II at subpressor doses reduces cardiac apelin expression, an effect 
abolished by concurrent AT1R blockage [Iwanaga et al 2006]. Furthermore, in 
hypertensive animal models of heart failure, as the phenotype progresses from left 
ventricular hypertrophy to ventricular failure, myocardial renin-angiotensin system 
expression increases, whilst the apelin-APLNR system is downregulated. However 
treatment with angiotensin II receptor blockers (ARBs) prevents progression to heart 
failure without altering expression levels for the renin-angiotensin or apelin-APLNR 
systems [Iwanaga et al 2006].  
 
There are further preclinical data supporting opposing expression patterns of the 
APLNR and AT1R under specific conditions. Mechanical stretch reduces APLNR 
expression within 24 hours [Szokodi et al 2002)] whilst increasing AT1R [Kijima et 
al 1996]. These data suggest that the transcription of the AT1R and APLNR genes  
expression are closely related.  
 
Transcription of the AT1R is kept under control, at least in part, by the retinoic acid 
receptor and the retinoid X receptor, both of which are nuclear receptors [Takeda et 
al 2000]. These proteins influence transcription [Bastien and Rochette-Egly 2004], 
and can be inhibited pharmacologically by all-trans retinoic acid (ATRA) treatment. 
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In vascular smooth muscle cells incubated with ATRA, AT1R expression is reduced 
[Takeda et al 2000]. In animal models of hypertension, with increased renin-
angiotensin expression, ATRA also reduces AT1R expression and increases APLNR 
expression. This is accompanied by a reduction in blood pressure, which appears to 
be mediated by nitric oxide [Zhong et al 2005].  
 
Downstream angiotensin II signalling is modified by the apelin-APLNR system. In 
whole animals, APLNR signalling opposes profibrotic angiotensin II effects on 
myocardium, preventing upregulation of plasminogen activator inhibitor type 1 
(PAI-1). Furthermore, angiotensin II transcription targets are influenced by APLNR 
activation. In cultured smooth muscle cells angiotensin II increases PAI-1 promotor 
activity, transcription and expression, which is inhibited by apelin treatment. 
Consistent with these results, angiotension II induced myocardial fibrosis, which is 
accompanied with upregulation of profibrotic genes, including PAI-1, is reduced in 
rodents treatment with apelin [Siddiquee et al 2011].  
 
Peptide metabolism 
At present, little is known about the circulating source of apelin or its metabolism. It 
is likely to function in both autocrine and paracrine fashions, with the cardiac atria 
being likely sources [Földes et al 2003]. The only identified enzyme involved in 
apelin breakdown is angiotensin-converting enzyme II, which hydrolyses both 
apelin-13 and apelin-36 [Vickers et al 2002]. ACE II diverts angiotensin II 
precursors from the ‘classical’ renin-angiotensin system, generating angiotensin 1-9 
and angiotensin 1-7 from angiotensin I and angiotensin II, respectively. The affinity 
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of ACE II for angiotensin II is some 400-fold higher than for angiotensin I, 
suggesting a major role in limiting angiotensin II accumulation and generating 
angiotensin 1-7 (Vickers et al 2002). There is increasing interest in the roles of 
ACE II and angiotensin 1-7 in cardiovascular physiology and disease. Angiotensin 1-
7 acts on the Mas receptor, mediates vasodilatation [Brosnihan et al 1996; Sasaki et 
al 2001], is cardioprotective [Loot et al 2002] and is antiproliferative [McCollum et 
al 2012], properties very similar to those of apelin. It is likely that the relationship 
between all of these peptides is highly complex and dynamic, but it is nevertheless 
conceivable that the apelin-APLNR system is one of a range of endogenous systems 
that modulates the functions of angiotensin II.  
 
In summary, there may be a reciprocal counter regulation between the apelin-
APLNR and renin-angiotensin systems. Given that the apelin-APLNR pathway 
appears to be inhibited by angiotensin II, this raises the possibility of therapeutic 
synergism by combining APLNR agonism with the inhibition of the renin-
angiotensin system. However, preclinical data highlight the potential for APLNR 
activation to enhance angiotensin II-mediated AT1R signalling, which is key to 







1.4 APELIN-APLNR SYSTEM: TRANSLATIONAL POTENTIAL IN 
CLINICAL DISEASE 
 
1.4.1  HEART FAILURE  
Data from apelin-deficient mice indicate that endogenous apelin activity may help 
maintain cardiac performance under conditions of cardiovascular stress [Kuba et al 
2007; Charo et al 2009]. However, the apelin-APLNR system appears to undergo 
downregulation during heart failure. Isolated cardiomyocytes subjected to repeated 
mechanical stretching, analogous to volume overload in congestive heart failure, 
exhibit marked downregulation of the APLNR within 24 hours [Szokodi et al 2002]. 
In an in vivo rodent model of hypertensive heart disease, the expression of cardiac 
apelin and the APLNR is increased or maintained at the left ventricular hypertrophy 
stage, but it declines dramatically with the transition to overt heart failure      
[Iwanaga et al 2006]. In humans, cardiac apelin-APLNR expression is reduced in 
patients with chronic heart failure secondary to dilated cardiomyopathy            
[Földes et al 2003; Pitkin et al 2010]. Interestingly, APLNR expression is preserved 
in those with an ischaemic aetiology [Földes et al 2003], perhaps reflecting the 
stimulatory effect of local hypoxia on apelin-APLNR expression [Atluri et al 2007; 
Sheikh et al 2008; Leeper et al 2009; Zeng et al 2009].  
 
Several groups have measured plasma apelin concentrations in patients with heart 
failure. In general, plasma apelin concentrations are maintained for mild to moderate 
left ventricular failure [Chen et al 2003], but they are reduced with severe left 
ventricular failure [Chen et al 2003; Chong et al 2006]. The apparent decline in 
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apelin-APLNR activity, in parallel with deteriorating cardiac performance, suggests 
a potential role for diminished apelin signalling in the pathophysiology of heart 
failure. Strategies to augment apelin signalling may therefore help to retard the 
progression of heart failure. Significantly, in an isoproterenol-induced model of heart 
failure, left ventricular dysfunction is partially rescued by co-administration of apelin 
[Jia et al 2006]. Tentative evidence indicating that alterations in endogenous apelin-
APLNR activity may modulate the progression of heart failure was provided in a 
cohort of patients with dilated cardiomyopathy [Sarzani et al 2007]. APLNR 
polymorphisms have been identified in a cohort of patients with heart failure. 
Genotyping identified two single nucleotide polymorphism, G212A and A445C. In 
patients with heart failure, presence of at least one A allele was associated with 
slower disease progress. The frequency of alleles was similar in healthy controls and 
patients with heart failure suggesting a modifying role rather than causal. [Sarzani et 
al 2007].   
 
The apelin-APLNR system is upregulated in response to device implantation, which 
may be mechanistic for the improvement in myocardial function. The APLNR is the 
most upregulated gene in response to left ventricular assist device implantation 
[Chen et al 2003] whilst plasma apelin concentrations increase following 
biventricular pacemaker insertion [Francia et al 2007].  
 
The unique haemodynamic profile of apelin in preclinical models suggests potential 
therapeutic utility in patients with established heart failure. Exogenous apelin 
potently enhances myocardial contractility, without inducing left ventricular 
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hypertrophy [Ashley et al 2005], and achieves this while simultaneously reducing 
ventricular preload and afterload [Berry et al 2004]. Crucially, the beneficial effects 
of apelin on cardiac contractility and loading conditions are maintained in preclinical 
models of heart failure. In vitro, apelin increases contractility in failing myocardium 
to the same [Farkasfalvi et al 2007] or greater [Dai et al 2006] extent as normal 
myocardium. In vivo, acute apelin infusion restores ejection fraction, increases 
cardiac output and reduces left ventricular end-diastolic pressure in rats with chronic 
heart failure [Berry et al 2004; Atluri et al 2007]. Thus, irrespective of alterations in 
receptor expression, these studies confirm that APLNR signalling capacity is not 
exhausted by exogenous apelin in established heart failure, an essential prerequisite 
for therapeutic strategies employing APLNR agonism. 
 
Preliminary data from clinical studies are encouraging. We have demonstrated that 
the local vascular and systemic haemodynamic effects of acute apelin infusion, 
including a rise in cardiac output, are preserved in patients with chronic stable heart 
failure [Japp et al 2010]. Importantly, these patients continued to receive currently 
available optimal pharmacological treatment, suggesting that the effects of apelin 
were additional to established heart failure treatments. In particular, all but one of the 
patients received treatment with an ACE inhibitor or an ARB. Preclinical data report 
direct interactions between the renin-angiotensin and apelin-APLNR systems, raising 
the possibility that some of apelin’s actions are mediated through antagonism of 
angiotensin II [Chun et al 2008; Siddiquee et al 2011]. Nonetheless, our findings 
imply a role for apelin that is independent of angiotensin II signalling pathways, and 
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they further suggest the potential for pharmacological synergism through combined 
APLNR agonism and renin-angiotensin system inhibition. 
 
One further area of translational potential in heart failure is utilising apelin as a 
biomarker (Table 1.1) [Chen et al 2003; Földes et al 2003; Chong et al 2006; Goetze 
et al 2006; Francia et al 2007; Miettinen et al 2007]. As discussed above, plasma 
apelin concentrations appear to decrease in patients with advanced heart failure, and 
this process may coincide with a decrease in cardiac performance [Chen et al 2003; 
Földes et al 2003; Chong et al 2006]. The largest study, (n >200) by Chong et al 
[2006], reported a reduction in plasma apelin concentrations in patients with heart 
failure, across all classes. Whilst there was preponderance towards more severe heart 
failure, with the majority in New York Heart Association (NYHA) class III or IV, no 
relationship between severity and plasma apelin concentration was identified. 
Conversely, Chen et al [2003] proposed that plasma apelin was dynamic in heart 
failure, with an increase in plasma apelin concentration reported in mild heart failure, 
which reduced to baseline levels in individuals with severe heart failure [Chen et al 
2003].  
 
Although studies have reported conflicting findings, some discrepancies are likely to 
be explained by differences in patient populations. Perhaps more importantly, there 
are significant concerns over the currently available assays for apelin and how these 
have been used. At present there are no assays available to detect all isoforms, such 
as (Pyr1)apelin-13, which is the most potent and abundant isoform in cardiac tissue 
[Maguire et al 2009]. Equally, there is an apparent lack of sensitivity and marked 
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variations in measured concentrations, with around a 40-fold discrepancy              
(90-3580 pg/mL) [Chen et al 2003; Földes et al 2003] being reported among healthy 
control populations. However, this is likely to reflect insufficient extraction in some 
studies, resulting in non-specific binding and reporting falsely elevated plasma 
concentrations. Interpretation is further complicated by an incomplete understanding 
of factors regulating the synthesis, post-translational processing and metabolism of 
apelin. 
 
The therapeutic potential of APLNR agonism is an exciting area for translational 
research in heart failure. Further studies in animal models with predictable 
progression to heart failure should determine the ability of APLNR agonism to 
prevent or delay the onset of a decline in cardiac performance. Detailed clinical 
research is currently limited by the lack of long acting, orally active therapeutic 
agents. While long term APLNR agonism may have therapeutic potential in patients 
with chronic stable heart failure, chronic dosing is not practicable or deliverable in 
the current context of the parenteral administration of short acting apelin peptide. 
The advent of oral APLNR agonists will permit the further exploration of potential 
interactions between the renin-angiotensin and apelin-APLNR systems, which in turn 
will help to clarify the pathogenic significance of altered apelin signalling in heart 
failure and the potential for therapeutic synergism with combined APLNR agonism 
and renin-angiotensin inhibition. In addition, the effects of sustained APLNR 
agonism on cardiac contractility and systemic haemodynamics require 
characterisation and are an essential prerequisite for clinical trials in patients with 
acute decompensated or chronic heart failure. Finally, longitudinal studies of plasma 
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apelin concentrations in patients with chronic heart failure will help to determine the 
utility of apelin as a novel biomarker. However, such studies are dependent on the 
development of an assay that identifies all of the major apelin isoforms. 
 
 
1.4.2  VASCULAR DISEASE 
Apelin appears to have beneficial effects on vascular health. In diabetic mice, it 
increases vascular nitric oxide generation and reverses endothelial dysfunction   
[Zhong et al 2007b; Zeng et al 2009]. In Apolipoprotein E (ApoE)-deficient mice, 
apelin infusion inhibits atherogenesis and completely abrogates angiotensin II 
accelerated atherosclerosis: an effect that is independent of blood pressure          
[Chun et al 2008]. Indeed, double knockout mice, deficient in both apelin and ApoE, 
have accelerated atherosclerosis in comparison with isolated ApoE-deficient mice. 
These data imply an important antiatherogenic role for endogenous apelin, as well as 
a potential benefit from exogenous apelin in atherosclerosis                               
[Zhang et al 2006; Chun et al 2008]. In contrast, one group has reported that the 
double knockout of the APLNR and ApoE reduced atherosclerotic lesion formation 
[Hashimoto et al 2007], suggesting that the APLNR is required for the progression of 
atherosclerosis. These contrasting findings are difficult to reconcile, although it is 
notable that these studies used very different feeding regimes. Future studies 
exploring the effects of pharmacological APLNR antagonism in ApoE-deficient 
mice may help to clarify the situation and reveal if there are off-target effects in one 
or other of the models. 
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Apelin treatment has reduced aneurysm formation by almost 50% in a mouse model 
of elastase-induced abdominal aortic aneurysm formation [Leeper et al 2009]. 
Corresponding reductions of macrophage infiltration within the arterial wall, and the 
local expression of a macrophage colony-stimulating factor (with strong trends 
towards reductions in tumour necrosis factor α, interleukin 6 and other                  
proinflammatory cytokines), suggest that the predominant mechanism by which this 
occurs is a direct anti-inflammatory effect within the vessel wall. 
 
The therapeutic potential of APLNR agonism in human vascular disease has yet to 
be explored. Apelin causes nitric oxide-mediated vasodilatation in vivo in forearm 
resistance vessels of healthy subjects [Japp et al 2008], but is not yet known whether 
it reverses the endothelial dysfunction seen in pathophysiological states such as 
diabetes mellitus and hypercholesterolaemia. However, in humans, apelin 
concentrations are reduced in individuals with dyslipidaemia [Tasci et al 2007] and 
coronary artery disease [Li et al 2008]. Furthermore, reductions in low-density 
lipoprotein (LDL) cholesterol concentrations as a result of dietary or statin 
intervention are associated with an increase in plasma apelin concentration        
[Tasci et al 2009]. Given the promising preclinical data, the potential role of APLNR 
agonism in preventing human vascular disease now merits detailed investigation. 
However, while studies have shown a predominant vasodilator action, 
vasoconstriction has been seen in vessels denuded of endothelium                  
[Maguire et al 2009]. This is common with other vasodilators, such as acetylcholine, 
and it may have implications for the effects of apelin in patients with vascular 
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disease. Contrary to this possibility, we have recently shown that vasodilatation to 
apelin is preserved in patients with heart failure [Japp et al 2010]. 
 
APNLR polymorphisms have been identified in the 212 loci in patients with 
cornonary artery disease. Whilst with the frequency of 212 polymorphisms similar in 
coronary artery disease and healthy populations, in patients with coronary artery 
disease and hypertension, the GG genotype is associated with hypertension, which 
may suggest a modifying role in this group [Falcone et al. 2012]. The biological 
function and significance of 212 polymorphisms is unclear at present, however this 
loci may be represent an important modifier role in cardiovascular disease. 
 
 
1.4.3  MYOCARDIAL INFARCTION AND ISCHAEMIA-REPERFUSION INJURY  
Different models of myocardial ischaemia have been used to assess changes in apelin 
expression, with hypoxia serving as a key stimulus. There is a time-dependent 
upregulation of apelin in cardiomyocytes maintained at low oxygen tensions under 
the control of hypoxia inducible factor 1α [Ronkainen et al 2007]. In Langendorff 
models of myocardial infarction and ischaemia-reperfusion, both APLNR and apelin 
are upregulated [Kleinz and Baxter 2008; Zeng et al 2009], especially at the 
watershed areas of infarct zones [Sheikh et al 2008]. This upregulation has been 
reported to return rapidly to baseline following reperfusion [Kleinz and Baxter 2008] 
or persist for up to 12 weeks [Sheikh et al 2008]. Determining the factors involved in 
maintaining upregulation is important, as this could serve to prolong the beneficial 
actions for apelin and may be of therapeutic benefit. 
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While it is plausible that the main purpose of apelin-APLNR upregulation is to 
prevent haemodynamic compromise by enhancing coronary blood flow and 
contractility, there is evidence that apelin acts as a cardioprotective agent to reduce 
the extent of infarction [Simpkin et al 2007]. Restoration of blood flow is a critical 
step in the resolution of myocardial infarction, but reperfusion does cause further 
damage to the myocardium and vasculature through ischaemic-reperfusion injury. 
The factors involved in mediating this injury include adenine triphosphate (ATP) 
depletion and mitochondrial dysfunction, reactive oxygen species and inflammation. 
One of the key mechanisms that protects against this injury is the activation of the 
salvage kinases, notably the reperfusion injury salvage kinases (RISK). This pro-
survival pathway reduces ischaemia-reperfusion injury by preserving mitochondrial 
function. Apelin increases both the phosphorylation and activity of key components 
within the RISK pathway [Smith et al 2007]. One of the hallmarks of mitochondrial 
dysfunction is the opening of mitochondrial permeability transition pores (mPTP), 
causing loss of membrane integrity and energy production. Apelin delays mPTP 
opening, preserves cell structures and reduces mitochondrial damage [Simpkin et al 
2007]. 
 
In the presence of RISK pathway inhibitors, apelin continues to have 
cardioprotective effects [Kleinz and Baxter 2008], suggesting alternative 
mechanisms of action. Indeed, during ischaemia-reperfusion injury, apelin increases 
endothelial nitric oxide synthase expression and reduces oxidative stress by 
preventing superoxide dismutase degradation [Zeng et al 2009]. Apelin also greatly 
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reduces the generation of reactive oxygen species as a result of catecholamine-
induced myocardial damage [Jia et al 2006]. Functionally, these protective effects 
translate into reductions in tissue damage markers, decreased infarct volume and the 
preservation of ventricular function [Zeng et al 2009]. 
 
These studies highlight apelin as an agent that protects against myocardial injury, 
although data are presently limited to preclinical studies. Obvious boundaries make 
preconditioning agents difficult to implement in clinical practice, but APLNR 
agonism may have a therapeutic role in patients following an acute myocardial 
infarction, with potential benefits in both restoring or maintaining left ventricular 
function and improving survival. 
 
1.4.4  HYPERTENSION 
Apelin receptor agonists represent a potentially novel class of antihypertensive 
agents. In preclinical models, exogenous apelin administration lowers blood pressure 
through peripheral vasodilatation. The depressor effect of apelin is greatly enhanced 
in hypertensive animals compared with normotensive controls [Lee et al 2005]. The 
apelin-APLNR system has been investigated in the spontaneously hypertensive rat 
[Zhang et al 2006], in which the apelin-APLNR system is downregulated in 
ventricular and aortic tissues as hypertension develops suggesting a role in 
maintaining normal blood pressure. When these hypertensive rodents are randomised 
to an exercise regime or a sedentary lifestyle, there is upregulation of apelin-APLNR, 
along with a corresponding reduction in blood pressure [Zhang et al 2006]. However, 
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a mechanistic role for the apelin-APLNR system in this context is not clear, and 
further investigation is required to tease out any causative role.  
 
Pharmacological inhibition of AT1R expression in the spontaneously hypertensive 
rat results in a fall in blood pressure and an increase in apelin-APLNR expression. 
The increase in apelin-APLNR expression may contribute significantly to the 
hypotensive effect observed [Zhong et al 2005]. Given the apparent suppression of 
APLNR expression by angiotensin II, the antihypertensive effect of APLNR agonism 
may be enhanced by concomitant treatment with agents that inhibit the renin-
angiotensin system. In our preliminary clinical studies, systemic apelin infusion had 
a modest blood pressure-lowering effect in normotensive middle-aged subjects [Japp 
et al 2008].  
 
 
1.4.5  IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION 
The apelin-APLNR system is downregulated in preclinical models of pulmonary 
hypertension. In monocrotaline models, both apelin and APLNR expression are 
reduced in the right ventricle [Falão-Pires et al 2009]. Hypoxic models report an 
initial increase in right ventricular apelin expression of tissue concentration [Chandra 
et al 2011; Drake et al 2011], which is greatly reduced as right heart failure develops 
[Drake et al 2011]. Furthermore, therapies that prevent pulmonary hypertension in 
these animal models are associated with increased apelin expression supporting a key 
role for the apelin-APLNR system in pulmonary hypertension [Drake et al 2011]. In 
hypoxic models of pulmonary hypertension, rodents that are apelin-deficient develop 
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more severe pulmonary hypertension than wild types, with the pulmonary 
vasculature demonstrating obliteration of small calibre arteries within the lung 
[Chandra et al 2011]. Adminstration of exogenous apelin can either prevent or rescue 
the pulmonary hypertension phenotype in this model [Dai et al 2006]. 
In cultured human pulmonary artery endothelial cells (PAEC) harvested from 
patients with idiopathic pulmonary arterial hypertension (IPAH) there is reduced 
apelin expression and increased smooth muscle proliferation. This proliferation can 
be inhibited with exogenous apelin, which appears to be mediated through signalling 
involving peroxisome proliferator-activated receptor gamma (PPARγ) and      
beta (β)-catenin complexes [Alastalo et al 2011]. Furthermore, apelin inhibits 
fibroblast growth factor-2 (FGF-2) regulation in PAECs from patients with IPAH, in 
a mechanism involving micro ribonucleic acids (miRNAs) (424 and 503). The 
importance of miRNAs 424 and 503 is highlighted by their ability to rescue and 
prevent pulmonary hypertension in animal models [Kim et al 2012].  
Human and clinical data are limited, but evidence suggests that apelin may be 
pathophysiological and represents a therapeutic target. Lung tissue from patients 
with IPAH has reduced apelin concentration (Kim et al 2011) and plasma apelin 
concentration is reduced in patients with IPAH [Goetze et al 2006; Andersen et al 
2009; Kim et al 2011], with one study reporting levels lower than those observed in 
left ventricular dysfunction. 
The apelin-APLNR system may be of critical importance in IPAH, with both 
pathophysiological and therapeutic potential. There is no disease modifying therapy 
available to treat patients with IPAH, however data from these preclinical studies 
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would support a role for the apelin-APLNR system in reversing vascular 
remodelling, whilst augmenting right ventricular function.  
 
1.4.6  METABOLIC SYNDROME 
Apelin is produced by adipose tissue and influences glucose and lipid metabolism as 
an adipocytokine. Apelin-deficient animal models exhibit reduced insulin sensitivity, 
which can be corrected by the administration of exogenous apelin [Yue et al 2010]. 
Conversely, exogenous apelin reduces peak plasma glucose concentration following 
a glucose load by increasing glucose turnover [Dray et al 2008], and this effect is 
preserved in insulin-resistant animal strains [Dray et al 2008]. The exact cellular 
mechanisms leading to increased glucose uptake are not understood completely. 
Apelin increases glucose uptake through the phosphorylation of insulin-dependent 
pathway components, such as Akt, although increased glucose uptake is still 
observed in the presence of the inhibition of this pathway, suggesting that the 
pathway is both insulin-dependent and insulin-independent. 
 
In preclinical studies, apelin alters feeding habits. In rats with diet-induced diabetes, 
exogenous apelin decreases food and water intake, but it has no effect on rodents 
receiving a normal diet [Clarke et al 2009].  
 
The effect of exogenous apelin on glucose handling in humans is currently unknown. 
However, increases in plasma concentrations have been seen during oral glucose 
tolerance tests and in healthy individuals and those with type 2 diabetes mellitus 
(T2DM) [Li et al 2006]. Interestingly, plasma apelin concentrations are reduced in 
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patients with newly diagnosed T2DM [Erdem et al 2008] but increased in obese non-
diabetic individuals [Boucher et al 2005]. This may suggest that the initial increases 
in apelin seen in obesity serve to delay the development of T2DM by preserving 
glycaemic control. 
 
APLNR agonism may offer therapeutic potential for the treatment of metabolic 
syndrome and diabetes mellitus, and it may provide benefits beyond glycaemic 
control in view of the interaction with the renin-angiotensin system. All functional 
data are limited to preclinical models, and while the observational data are in keeping 
with a role in glucose homeostasis, the effect of APLNR agonism needs to be 
assessed in vivo in humans.  
 
1.4.7   APLNR AS A THERAPUETIC TARGET 
Conformational changes in receptor structure influences intracellular signalling 
cascades. Agonist binding, in addition to triggering phosphorylation of GPCR 
kinases, additionally promotes  β-arrestin recruitment and binding to the receptor, 
which functions to inhibit signal. Additionally, β-arresting binding results in receptor 
endocytosis via clarthrin-dependant mechanism, which further inhibits agonist 
responses. Balanced agonists stimulate both G-protein effects and β-arrestin 
pathway, whereas biased agonists can direct signalling preferentially. [Shukla et al 
2014] 
 
There are concerns regarding tachyphalaxis, which may limit the therapeutic 
potential of APLNR agonism. In cellular models, upon agonist binding the APLNR 
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localizes rapidly to the perinuclear compartment in clathrin and β-arrestin pathways. 
Interestingly shorter, more potent forms of apelin appear to trigger more 
internalization. [El Messari et at 2004] 
 
There is interest in developing agonists that are biased towards the desired effects of 
APLNR signalling. ML233 is a small molecule APLNR agonist that has been shown 
to stimulate G protein pathways, however also results in β-arrestin internalization, 
and therefore may be of limited utility in further exploring the therapeutic potential 
of the APLNR. [Khan et al 2011] 
 
MM07 is a synthetic molecule that appears to function as a biased agonist for 
APLNR. In cellular models, β-arrestin mediated internalsation assays MM07 results 
in reduced receptor internalization, being around two orders of magnitude less potent 
than (Pyr1)apelin-13.  The cardiac vascular effects have been assessed in animal and 
human models. In whole animal models MM07 results in positive inotropism with 
increased cardiac output of around 20%, but with out inducing hypotension or reflex 
tachycardia. This effect is similar to that of other commonly used inotropes, such as 
dobutamine or milrinone. In man MM07 mediates vasodilation in local forearm 
studies that is two fold that of (Pyr1)apelin-13, dose dependent and retains efficacy 
over repeated doses. [Brame et al 2015] 
 
Development of biased agonists may unlock the therapeutic potential of the APLNR 




1.4.7  CONCLUSIONS 
Both preclinical and emerging clinical studies suggest an important role for apelin in 
health and disease. However, its contribution to the pathophysiology of 
cardiovascular diseases needs to be more fully characterised and better defined. 
Therapeutic manipulation of the apelin-APLNR system represents a novel and 
potentially exciting therapeutic target, especially in heart failure, vascular disease, 
myocardial ischaemia and metabolic syndrome. 
 
1.5 STUDY AIMS 
 
The aim of this work is to understand and characterise the cardiovascular actions of 
the apelin-APLNR system. To date, we have investigated regional and systemic 
cardiovascular responses to apelin in healthy volunteers and patients with stable 
heart failure during brief infusions, at rest and with no modification to the renin-
angiotensin system. 
 
There is growing evidence of an interaction between the apelin-APLNR and renin-
angiotensin systems from in vitro and preclinical data. We wish to assess any 
physiologically relevant relationship in the human vasculature under conditions of 
renin-angiotensin II activation. Therefore, we need to evaluate whether apelin-
APLNR signalling retains its efficacy in the presence of elevated angiotensin II as 
this is critical in understanding any therapeutic role; many potential applications of 
apelin will be in diseases that have increased renin-angiotensin II activity. 
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Furthermore, characterising the effect of prolonged APLNR agonism is essential. 
The APLNR internalises rapidly, may exhibit tachyphylaxis and is downregulated in 
heart failure. Taken together, this may suggest that the APLNR may become 
saturated and the effects short-lived. This would potentially limit its utility as a 
therapeutic target in heart failure. 
 
Finally, deficiencies in the apelin-APLNR system result in reduced exercise 
performance. We wish to asses the effect of exogenous apelin during exercise, in 
order to ascertain whether pharmacological activation of the APLNR during exercise 




These following hypotheses will be addressed in this respect: 
1. Subacute upregulation of the renin-angiotensin system will reduce the 
activity of APLNR agonism in local vasculature and systemic 
circulation by reducing APLNR density in target tissues (Chapter 3). 
 
2. Local and system cardiovascular actions of (Pyr1)apelin-13 will be 
reduced during acute angiotensin II elevation, through reduced 
availability of the APLNR, and this may even potentiate AT1R 
signalling (Chapter 4).  
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3. Brief systemic (Pyr1)apelin-13 infusion will mediate an increased 
cardiac index and reduced mean arterial pressure and systemic 
vascular resistance in patients with chronic stable heart failure 
(Chapter 5). 
 
4. Prolonged infusion of (Pyr1)apelin-13 will result in sustained systemic 
cardiovascular actions in healthy volunteers and patients with chronic 
stable heart failure (Chapter 6). 
 
5. Infusion of (Pyr1)apelin-13 will increase exercise performance in 

























2.1    RECRUITMENT 
 
Healthy volunteers 
Subjects were recruited through a local advertisement placed at the campuses of both 
the University of London and Imperial College London and notifications on the 
Edinburgh Electronic Medical Curriculum (EEMeC). Permission for medical student 
recruitment was approved following an application to the University of Edinburgh.   
 
Patients with chronic stable heart failure 
Potential participants were identified from the Royal Infirmary of Edinburgh heart 
failure database and screening of outpatients’ clinical notes. An information sheet 
was sent to all patients fulfilling the inclusion and exclusion criteria. Prior to any 
contact being made with potential participants, approval was obtained from their 
regular Consultant Cardiologist.  
 
Patients with chronic stable heart failure were required to have fractional shortening 
<20% and left ventricular ejection fraction <30%, on an echocardiogram within               
6 months of enrolment, and NYHA class II-IV symptoms. Patients were maintained 
on maximally tolerated doses of evidenced-based therapies, including renin-
angiotensin and beta-adrenergic inhibitor therapy, although they abstained from their 
regular medications on the morning of study. 
 
Patients were excluded if they were involved in any other medical trial or had severe 
and significant co-morbidity, haemodynamically significant aortic stenosis, 
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malignant arrhythmias, severe hypertension (systolic blood pressure 
(SBP) >190 mmHg), a pacemaker in situ or women of child-bearing potential. 
 
2.1.1  ETHICS 
All studies were conducted following the approval of the Lothian Research 
Committee (REC 09/S1101/4 and REC 10/S1101/18) and the London Riverside 
Committee (REC 11/LO/2063) and were in accordance with the World Medical 
Association’s Declaration of Helsinki. Prior to commencing the studies, the 
participants received a patient information sheet, and written informed consent was 
obtained. 
 
2.1.2  REGISTRATION 














2.2 UPREGULATION OF THE RENIN-ANGIOTENSIN SYSTEM 
 
2.2.1  ENDOGENOUS, SUBACUTE 
The renin-angiotensin system is dormant in healthy individuals consuming a diet 
replete in sodium. However, this can be activated by consuming a sodium deplete 
diet [Newby et al 1997b]. The subjects attended twice at least one week apart, having 
been randomised in a single blind crossover design to a sodium depleted or normal 
sodium replete diet, as previously described. Briefly, for sodium depletion, subjects 
were asked to adhere to a diet containing <12 mmol of sodium per day for 3  days 
prior to the study visit (see Appendix p186). To ensure prompt sodium depletion, the 
subjects were given a single oral dose of furosemide (20 mg) on day one of the diet. 
For all sodium depletion studies, urine was collected from each individual 24 hours 
before each visit, in order to assess sodium excretion.  
 
2.2.2  EXOGENOUS, ACUTE 
Exogenous angiotensin II (Clinalfa AG, Läufelfingen, Switzerland) was infused 
intra-arterially in local studies or through a 17-gauge venous cannula in the 









2.3 ASSESSMENT OF LOCAL VASCULAR FUNCTION  
 
2.3.1  VENOUS OCCLUSION PLETHYSMOGRAPHY 
The vasomotor function of arteries can be assessed as a measure of endothelial 
function. Local intra-arterial administration combined with venous occlusion 
plethysmography [Wilkinson and Webb 2001] in the forearm, provides a method of 
directly assessing resistance vessel function without the need for systemic 
administration of investigational agents that can induce counter regulatory 
neurohormonal responses. Furthermore, this technique assesses vasomotor response 
in the presence of endogenous physiological regulators of vascular tone and function, 
providing a true response of vasomotor activity in vivo [Webb 1995].  
 
Venous occlusion plethysmography detects flow changes by assessing resistance in 
strain gauges placed around circumference of the forearm (Figure 2.1). Venous 
outflow is stopped abruptly by inflating cuffs in the upper arm above venous 
pressure but below arterial venous pressure, hence occluding venous outflow; typical 
traces are shown below (Figure 2.2). Therefore, blood can flow into the forearm but 
it cannot drain away, thus increasing forearm volume that is proportional to arterial 
flow. The vascular bed in the hand is typically excluded through cuff inflation 












































2.3.2  INTRA-ARTERIAL CANNULATION 
The brachial artery of the non-dominant forearm was cannulated with a 27-standard 
wire gauge steel needle (Coopers Needle Works Ltd, Birmingham, UK) following 
subcutaneous infiltration of local anaesthetic (Hameln Pharmaceuticals Ltd, 
Gloucester, UK). The cannula was attached to a 16-gauge epidural catheter (Portex 
Ltd, Hythe, UK) and patency maintained with infusion of saline (0.9%; Baxter 
Healthcare Ltd, Norfolk, UK) via an IVAC P6000 syringe pump (Alaris Carefusion, 
Basingstoke, UK) total rate of intra-arterial infusion was 1 mL/min in all studies 
(Figure 2.3). 
 
2.3.3  BLOOD FLOW MEASUREMENT  
Mercury-in-silastic strain gauges were applied to the widest part of the forearm. Both 
arms were elevated above the heart to ensure adequate venous drainage. During the 
assessment of blood flow, the upper arm cuffs were inflated repeatedly to 40 mmHg 
to occlude venous outflow for 9 out of 12 seconds. The wrist cuffs were inflated to 
200 mmHg during measurement periods, in order to exclude the hand circulation. 
The cuffs were inflated using a rapid cuff inflation system (DE Hokanson Inc, 
Bellevue, WA, USA). Resistance in the strain gauge (Mercury-in-silastic; DE 
Hokanson Inc, USA) was measured with an EC6 strain gauge plethysmograph (DE 











Figure 2.3.  Arterial cannulation (needle) with mercury-in-silastic strain gauges placed around 
the forearm. Wrist cuff, which inflates to 200 mmHg to exclude hand circulation, and arm cuff, 




2.3.4  PLETHYSMOGRAPHY DATA ANALYSIS 
Blood flow from each individual was analysed on ChartTM and calculated on an 
Excel template spread sheet (Excel 2008, Microsoft Corporation, WA, USA). Blood 
flow assessment was calculated from the last five recordings in each 3-minute 
recording period, and the average was then calculated.  
 
2.4 ASSESSMENT OF SYSTEMIC HAEMODYNAMICS 
 
Cardiac output is challenging to assess, and no technique is entirely satisfactory. The 
Fick principle is considered the gold standard in this respect. However, it is limited 
by the requirement for specialist face masks and arterial and venous blood samples: 
in the context of repeated measures and prolonged infusions of study medications, an 
indwelling arterial cannula would be required. Thermodilution or tracer techniques 
can also be used, although these too are invasive and require central venous 
cannulation. Thoracic electrical bioimpedance is a technique first described in 1940 
that has subsequently been refined and can be used to assess cardiac output non-
invasively [Nyboer et al 1970; Tsadok 1999].  
 
2.4.1  THORACIC ELECTRICAL BIOIMEPEDANCE 
Thoracic electrical bioimpedance is a non-invasive method for assessing cardiac 
output electrodes, 2 on the neck and 2 on the thorax  (Figures 2.4 and 2.5), and a 
































Impedance, which is the opposition of charge flow in alternating current circuits, is 
analogous to resistance in direct current circuits. Data are acquired by applying a 
small current through electrodes in the neck and midaxillary line. Nyboer et al 
[1970] were the first to describe changes in thoracic impedance as inversely related 
to the stroke index, and this has been refined over time [Thomas 1992]. 
 
The thorax is modelled as a cylindrical conductor that has a further smaller cylinder 










Each of the component tissues within the thorax contribute to the overall resistance, 
the properties of which are largely unaltered throughout the cardiac cycle [Osypka 
and Bernstein 1999]. Of all the tissues, blood has the lowest resistance, so the current 
will flow through the great vessels in the thorax. Therefore, changes in impedance 
throughout the cardiac cycle can be considered as a function of changes of 
impedance within the great vessels, with almost all of the early impedance changes 
related to blood volume change in the aorta [Kim et al 1988]. 
 




Both aortic compliance and thoracic fluid content impact on impedance. Any 
reduction in aortic compliance, through age, for example, will reduce impedance and 
similarly increase fluid content in the thorax, which in turn will decrease compliance. 
Conditions such as emphysema, with increased air content, will increase impedance 
[Osypka and Bernstein 1999]. 
 
Thoracic electrical bioimpedance has been validated against accepted invasive 
methods of measuring cardiac output. Correlation is accepted to be high, with values 
ranging from 0.77 - 0.99 . [Northridge et al 1990; Bernstein et al 1986; Salandin et al 
1988; Thomas et al 1992; Shoemaker et al 1994; Drazner et al 2002; Sageman 2002; 
Yung et al 2004; Engoren and Barbee 2005; Suttner et al 2006; Gujjar et al 2008; 
Tonelli et al 2011]. Mean differences between cardiac output assessed invasively and 
thoracic bioimpedance ranged from 2.7-9.0% [Northridge et al 1990; Thomas et al 
1992]. Importantly, changes trends in cardiac output over time assessed by thoracic 
bioimpedance correlate to invasive techniques over time. [Shoemaker et al 1994] 
Furthermore, thoracic electrical bioimpedance can detect changes in cardiac output 
in response to drug infusion, which is best when considering changes from baseline 
rather than absolute changes [Thomas et al 1992].  
 
There are limited data assessing thoracic electrical bioimpedance in chronic stable 
heart failure, although correlation with invasive techniques of assessing cardiac 
output exists and appears to be a suitable technique for assessing cardiac function in 
heart failure [Drazner et al 2002] and pulmonary hypertension [Tonelli et al 2011]. 
Typically, electrical bioimpedance will overestimate cardiac output in heart failure 
	
	 64 
relative to thermodilution. However, good agreement has been demonstrated with 
respect to assessing changes in cardiac output [Tanino et al 2009].  
 
 
2.4.2  IMPEDANCE CARDIOGRAPHY AND SPHYGMOMANOMETRY 
Cardiac index was measured non-invasively through thoracic bioimpedance (Hotman 
Hemo Sapiens, CA, USA). Prior to the infusion of study medication, all subjects 
rested in a supine position for at least 30 minutes to stabilise all measured 
haemodynamics, and the studies only proceeded once three recordings were within 
10% of a continuous average. 
 
At each time point, an index output was taken as the mean of three recordings, each 
one of which represented the average of 15 consecutive heartbeats. The cardiac index 





An electrocardiogram was monitored continuously, and blood pressure and heart rate 
were recorded with a semi-automated, non-invasive oscillometric 
sphygmomanometer (HEM 705CP, Omron, Tokyo, Japan). Mean arterial pressure 




2.2 Directly non-invasive measured parameters 
 Systolic and diastolic systemic arterial blood pressure (SBP, DBP, mmHg) 
 Heart rate (HR, beats/min) 
 Weight (W, kg) 
 Height (H, cm) 
2.3 Calculated Parameters 
 Mean systemic arterial blood pressure (MAP):   




DBPSBPMAP  mmHg 
 Mean pulmonary arterial pressure (PAPmean):  




PAPdiaPAPsystPAPmean  mmHg 
 Pulmonary vascular resistance (PVR):  
   
CO
PCWPPVR  PAPmean80  (dyn•sec• cm
-5) 
 Pulmonary vascular resistance index (PVRi): 
    BSA
CO
PCWPPAPmeanPVRi  80  (dyn•sec• cm-5•m2)  
 Systemic vascular resistance (SVR): 
   
CO
RAPmeanMAPSVR  80  (dyn•sec• cm-5) 
 System vascular resistance index (SVRi):  
    BSA
CO
RAPmeanMAPSVRi  80  (dyn•sec• cm-5•m2) 
 Body surface area (BSA):  
   (m2 , DuBois formula) 007184.0725.0425.0  HWBSA
Right Heart Catheterization Manual / 11348 / Version 4.0 / 2010-Aug-31/ Page 4 of 14  
 Cardiac index (CI):  
  
BSA
COCI   (L/min/m2) 
3. Personnel 
Only personnel with an expertise in right heart catheterization should be involved in the study 
related measurements. 
4. Study related measuring points 
 Baseline: Right-Heart Catheterization results for the definite diagnosis of PH must 
not be older then 8 weeks at Visit 1 (will be considered as baselines values). If the 
respective measurements have not been performed in context with the patient’s 
regular diagnostic work up, they have to be performed as a part of the study during 
the Pre-Treatment Phase (after obtaining informed consent) or at Visit 1 before 
randomization. 
 Visit 7 
 Termination Visit 
 Unscheduled hemodynamic measurements during study participation (at the 
discretion of the investigator) 
5. Documentation 
 All study relevant data collected in context with the hemodynamic measurements 
must be documented in the patient file and the electronic CRF. 
 Printouts from electronic devices (e.g. paper tracings of the pressure curves, print 
outs from the thermodilution device) will be signed by the physician who is 
responsible for the measurements, and need to be stored in the patient file. 






Systemic vascular resistance was calculated as mean arterial pressure minus mean 




2.4.3  THORACIC ELECTRICAL BIOIMPEDANCE CARDIOGRAPHY DATA ANALYSIS 
The average of three values for cardiac index, heart rate, mean arterial pressure and 
systemic vascular resistance were calculated on an Excel spreadsheet (Excel 2008). 
 
2.5 ASSESSMENT OF LEFT VENTRICULAR FUNCTION  
 
Echocardiography was performed using a Philips iE33 ultrasound scanner with     
3 MHz transducer (Philips Healthcare, Best, Netherlands. Left ventricular 
dimensions were assessed through two-dimensional in chronic heart failure studies. 
All studies were performed and analysed by the British Society of 




 dynes·s/cm5/m2  
80 x (mean arterial pressure-right atrial pressure) 
Cardiac Index 
Systemic vascular 









Left ventricular ejection fraction was assessed using the Teichholz method. 
 
2.6 CARDIOPULMONARY EXERCISE TESTING  
 
Cardiopulmonary exercise testing is a well-established technique employed to assess 
cardiovascular performance. Cardiac bioimpedance is less effective in exercise as the 
signal is distorted through motion artefact and elevated respiratory rate. However, in 
addition to haemodynamic and electrocardiograph information, respiratory measures 
of oxygen uptake and ventilation can be captured. Sports medicine has adopted 
cardiopulmonary exercise testing to assess and monitor athletic performance, but in 
clinical medicine valuable prognostic information can be acquired from exercise 
testing. 
 
In patients with heart failure, cardiopulmonary exercise testing is an excellent 
prognostic tool [Stelken et al 1996; Myers et al 2000; Guazzi et al 2005] and is 
widely used to stratify patients following cardiac transplantation [Mancini et al 
1991]. Furthermore, in patients with pulmonary arterial hypertension, 
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cardiopulmonary exercise testing predicts survival [Wensel et al 2012]. Exercise 
testing can assess responses to therapies in healthy volunteers and patient cohorts 
[O'Donnell et al 2004; Lewis et al 2006; de Man et al 2009; Li et al 2009; Vagaggini 
et al 2011]. Typically, an incremental exercise test is performed to determine the 
maximal workload of an individual, followed by endurance tests that are performed 
at 70-80% of maximal workload, with and without intervention.  
 
The main cardiopulmonary indices are reproducible on repeated testing. In healthy, 
trained individuals, low intra-subject variability is reported in sequential testing 
[Weston and Gabbett 2001] and these findings extend to patient populations with 
heart failure and pulmonary disease [Meyer et al 1997; Hansen et al 2004; Keteyian 
et al 2010]. This is not universal, though, and some investigators report high intra-
subject variations in repeated testing. Furthermore, on repeated testing, some studies 
report the equal likelihood of improvement or deterioration, suggesting that learning 
and conditioning are not major determinants of performance [Bensimhon et al 2008].  
 
Cardiopulmonary exercise tests were performed on a cycle ergometer (ViaSYS 
Healthcare, Carefusion, Basingstoke, UK) at Imperial College NHS Healthcare 
Trust’s exercise laboratory. Ventilation and gas exchange parameters were measured 
continually producing a breath-by-breath analysis of carbon dioxide and oxygen 
during exercise protocols. Breath-by-breath analyses were recorded throughout 
(Master Screen CPX Metabolic Cart, Carefusion, Basingstoke, UK) and data were 
collected automatically (JLAB LABManager, software version 5.3.0.4, Cardinal 
Health Germany, Hoechberg, Germany), Baseline pulmonary function was assessed 
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prior to exercise testing. Blood pressure was assessed at regular intervals during 
exercise and there was continuous electrocardiograph monitoring throughout each 
visit. Oxygen consumption rate (VO2), carbon dioxide production (VCO2), tidal 
volume (VT) and ventilation were measured throughout all exercise protocols. 
 
2.6.1  INCREMENTAL MAXIMAL CARDIOPULMONARY EXERCISE PROTOCOL  
Maximal workload was determined by incremental exercise testing. An initial rest 
period with the subjects seated on an ergometer was followed by 1 minute of unload 
cycling and thereafter an incremental increase in workload of 30 watts per minute, at 
1 watt increments, was applied until symptom limitation was reached. Patients were 
encouraged to maintain maximal workload, and maximum effort was determined by 
any of the following: 85% of maximum predicted heart rate, respiratory exchange 
ratio >1.1 or a VO2MAX plateau accepted as maximal effort. 
 
2.6.2  ENDURANCE CARDIOPULMONARY EXERCISE PROTOCOL  
Following incremental exercise tests, subjects attended on two further occasions to 
undertake an endurance exercise protocol. This was set at 80% of maximal work rate, 
as determined from the initial incremental exercise test. Following 2 minutes of rest, 
the subjects exercised with no resistance for 1 minute, and thereafter the appropriate 
workload was applied rapidly. 
 
2.7 VENOUS SAMPLING AND LABORATORIES 
 
2.7.1  FOREARM VENOUS SAMPLING 
	
	 69 
Venous cannulae (17-gauge) were inserted into the large antecubital veins of both 
arms to allow for drug infusion and the sampling of venous blood. Blood samples 
were drawn into ethylene diamine tetraacetic acid (EDTA) or serum gel 
(Monovette®, Sarstedt, Nümbrecht, Germany). 
 
2.7.2  URINE COLLECTION  
Urine was collected in non-sterile acidified containers and analysed for sodium 
content (Department of Clinical Biochemistry, Lothian NHS University Hospitals 
Trust, Scotland). 
 
2.7.3  SAMPLE PREPARATION 
Blood samples were drawn into EDTA, centrifuged at 2000 g for 15 minutes to 
obtain plasma and stored at -80oC until assayed. Subjects voided prior to 
commencing all studies and urine was collected throughout the systemic studies. 
Urinary sodium concentration was determined using an ion selective electrode. 
 
2.7.4  ANGIOTENSIN II AND PLASMA RENIN ACTIVITY ASSAYS 
Plasma angiotensin II concentrations (Peninsula Laboratories Europe Ltd, St Helens, 
UK) were determined by radioimmunoassay, following extraction using Bond Elut® 
columns (Agilent Technologies, Cheshire, UK). Plasma renin activity was  measured 
under standard conditions through the generation of angiotensin I, as determined by 







2.7.5  PLASMA APELIN CONCENTRATION 
Plasma apelin was assayed using standard, commercially available enzyme-linked 
immunosorbent assay (ELISA) (Phoenix Peptides, CA, USA) and processed in 
accordance with the manufacturer’s instructions.  
 
2.8 DATA ANALYSIS 
 
2.8.1   IMPEDANCE CARDIOGRAPHY AND SPHYGMOMANOMETRY ANALYSIS 
An average of three values for cardiac index, heart rate, mean arterial pressure and 
systemic vascular resistance was calculated on an Excel spreadsheet (Excel 2008). 
Data were analysed by analysis of variance (ANOVA) and paired two-tailed 
Student’s t-test using GraphPad Prism (GraphPad Software Inc, CA, USA) and 
presented as the mean and standard error of the mean (SEM), unless otherwise stated. 
Statistical significance was taken at the level of 5%. 
 
2.8.2   PLETHYSMOGRAPHY DATA ANALYSIS 
Blood flow from each individual was analysed on ChartTM and calculated on an 
Excel template spread sheet (Excel 2008). Blood flow assessment was calculated 
from the last five recordings in each 3-minute recording period, and the average was 
then calculated. Data were  analysed by ANOVA and paired two-tailed Student’s     
t-test using GraphPad Prism and presented as the mean and SEM, unless otherwise 





2.8.3   CARDIOPULMONARY EXERCISE TEST 
Absolute values of VO2MAX, mean arterial pressure, ventilation efficiency, endurance 
time and heart rate during (Pyr1)apelin-13 infusion will be compared with those 
during the placebo infusion by paired two-tailed Student’s t-test. All data were 
analysed using GraphPad Prism and presented as the mean and SEM, unless 
otherwise stated. Statistical significance was taken at the level of 5%. 
 
2.8.4   ASSAYS 
Data were analysed by paired two-tailed Student’s t-test using GraphPad Prism and 
presented as the mean and SEM, unless otherwise stated. Statistical significance was 
taken at the level of 5%. 
 
2.8.5   DRUGS 
APLNR agonism was investigated with pharmaceutical grade (Pyr1)apelin-13 
(Clinalfa AG, Läufelfingen, Switzerland, or  Genscript, NJ, USA). Dose ranges were 
ascertained from previous studies performed within the group that produced maximal 
physiological effects in techniques used. Previously forearm studies assessing local 
arterial responses to (Pyr1)apelin-13 were preformed over a three hundred fold range 
in concentration, from 0.1nanmol/min to 30nanomaol/min. No further local 
vasodilatation was observed beyond 3nanomol/min and dosing in acute local studies 
was derived from these data [Japp et al 2010]. Systemic infusions protocol doses 
were based on previous studies within the group and from my own experience during 
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studies. Systemic infusion dose response curves in healthy volunteers and patients 
with chronic stable heart failure demonstrated no efficacy beyond 30nanmol/min and 
therefore this dose was selected for prolonged infusion. [Japp et al 2011].   
 
Two different apelin peptide suppliers were used during the studies presented in this 
thesis, Genscript and Bachem. Genscript peptide was used in all studies performed in 
University of Edinburgh, (protocols in chapter 3-6) and Bachem peptide was used in 
studies performed in Imperial college London.  Potency of Genscript peptide was 
assessed during one unblended local arterial infusion study of  (Pyr1)apelin-13 that 
yielded similar results to previous local studies performed within the group. 
Furthermore, on completion for the first protocol, results were reviewed internally 
and, again, vascular response to Genscript peptide were similar to prior studies 
within the group. Bachem peptide was not re-evaluated and assumed to be of similar 
potency to previous studies. 
 
Protocols requiring angiotensin II infusions were conducted with pharmaceutical 
grade angiotensin II (Clinalfa AG, Läufelfingen, Switzerland). Control vasodilators 
were acetylcholine (Norvartis AG, Basel, Switzerland), sodium nitroprusside (Mayne 









CHAPTER  3 
 
LOCAL AND SYSTEMIC VASCULAR RESPONSES TO 
APELIN RECEPTOR AGONISM DURING  
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Introduction Expression of the Apelin-APLNR system is reduced in conditions of 
renin-angiotensin system activation. This study assessed local and systemic 
cardiovascular actions of (Pyr1)apelin-13 during subacute renin-angiotensin 
elevation.  
 
Methods   In a single blinded randomised crossover trial, patients were allocated a 
low sodium diet (<12 mmol sodium/day) or a normal diet, with visits separated by at 
least one week. Forearm blood flow was assessed with venous occlusion 
plethysmography during intra-arterial (Pyr1)apelin-13 (0.3, 1.0 and 3.0 nmol/min), 
acetylcholine (5, 10 and 20 µg/min) and sodium nitroprusside (0.5, 1.0 and             
2.0 µg/min) infusion. Cardiac index, systemic vascular resistance index, heart rate 
and mean arterial pressure were assessed with thoracic electrical bioimpedance and a 
semi-automated sphygmomanometer respectively during systemic (Pyr1)apelin-13 
(30, 100 and 300 nmol/min) or placebo infusion (0.9% saline). Plasma renin activity 
and angiotensin concentrations were measured at the beginning of each visit. 
 
Results   Sodium depletion increases plasma renin activity (4.2±0.9 versus       
0.8±0.2 ng/mL/hr; P <0.01) and plasma angiotensin II concentrations (11.6±1.9 
versus 5.1±1.0 pg/mL; P <0.01). All local and systemic vascular responses to 




Conclusion   During significant upregulation of the renin-angiotensin system 
cardiovascular responses to (Pyr1)apelin-13 are preserved. The apelin-APLNR 
system is predicted to replicate these results in disease states with increased renin-




The G protein-coupled receptor, APLNR, was identified in 1993 (O'Dowd et al 
1993), and of all G protein-coupled receptors it most closely resembles the 
angiotensin II type 1 receptor. These receptors share around a 50% sequence 
homology in the transmembrane domains and are present in similar tissue locations 
throughout the body [Lee et al 2000; Ashley et al 2006]. However, these two 
systems mediate opposing actions with regard to inflammation [Chun et al 2008], 
vascular tone [Gurzu et al 2006] and fluid balance [Azizi et al 2008]. 
 
The apelin-APLNR system is vasoactive and mediates vasodilatation [Lee et al 
2000] that is endothelial and nitric oxide-dependent [Tatemoto et al 1998; 
Hashimoto et al 2006; Jia et al 2007; Zhong et al 2007b). In cultured aortic tissue, 
apelin increases nitric oxide production in a dose-dependent manner, increasing 
nitric oxide activity and expression whilst promoting L-arginine transport              
[Jia et al 2007]. Apelin mediates vasorelaxation in myography studies           
[Salcedo et al 2007], although vasoconstriction is also reported in denuded human 
saphenous veins [Katugampola et al 2001]. In whole animal models, the 
administration of apelin results in rapid transient reduction in mean arterial pressure 
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[Lee et al 2000] and increases plasma nitrate and nitrite levels                      
[Tatemoto et al 2001]. In man, local regional apelin infusion in the brachial arterial 
and coronary arterial circulation produces vasodilatation, whilst systemic infusions 
reduce mean arterial pressure [Japp et al 2008; Japp et al 2010].  
 
The inotropic action of apelin has been characterised in a range of preclinical 
models. In isolated cardiomyocytes it is reported to be the most potent inotrope 
discovered, effective at subnanomolar concentrations [Szokodi et al 2002]. 
Furthermore, the actions of apelin on failing myocardium appear to be more potent 
than normal myocardium [Dai et al 2006; Farkasfalvi et al 2007]. In whole perfused 
hearts and animal models, apelin increases cardiac output, and importantly under 
constant loading conditions there is increased contractility; therefore, inotropic action 
is in part through direct myocardial action rather than reducing afterload [Ashley et 
al 2005]. Whilst clinical studies are limited, data from in vivo studies confirm its 
inotropic action in man [Japp et al 2010]. 
 
The interaction between apelin and renin-angiotensin is essential to understand, with 
evidence from preclinical studies suggesting that there is significant interaction 
between these two systems. Beyond the opposing actions in vascular tone, fluid 
homeostasis and inflammation, there appear to be important subcellular interactions 
[Chun et al 2008; Sun et al 2011]. The formation of APLNR and AT1R heterodimers 
has been reported in preclinical models, with important functional consequences. 
Critically, the non-activated APLNR is posited to mediate angiotensin II antagonism, 
with the activated APLNR potentiating AT1R signalling [Sun et al 2011]. 
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Furthermore, in a range of preclinical studies, angiotensin II elevations downregulate 
apelin-APLNR system expression [Ishida et al 2004; Iwanaga et al 2006]. Therefore, 
these two systems interact at physiological, receptor and subcellular levels. The aim 
of this study is to assess the effect of subacute renin-angiotensin elevation on the 
local and systemic vascular actions of APLNR agonism. 
 
3.2.1  HYPOTHESIS 
Subacute upregulation of the renin-angiotensin system will reduce the cardiovascular 
effects of APLNR agonism in local peripheral and systemic circulation.  
 
3.3     METHODS 
 
3.3.1  SUBJECTS 
Twelve healthy volunteers, aged between 19 and 22 years, participated in these 
studies, all of which were performed with the approval of the local Ethics Research 
Committee, in accordance with the Declaration of Helsinki and with the written 
consent of all volunteers. Subjects were excluded if they were receiving any regular 
medication, had any significant past medical history, were current smokers or had 
participated in research studies within 3 months of enrolment. 
 
3.3.2  STUDY DESIGN 
Twelve subjects attended on two occasions, at least one week apart after being 
randomised in a single blind crossover design to a sodium deplete or normal 
sodium replete diet, as described previously (Figure 3.1) [Newby et al 1997b].  
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Briefly, for sodium depletion, subjects were asked to adhere to a diet containing    
<12 mmol of sodium per day for 3 days prior to the study visit (Appendix, p 186). To 
ensure prompt sodium depletion, subjects were given a single oral dose of 
furosemide (20 mg) on day one of the diet. For all sodium depletion studies, urine 
was collected from each individual 24 hours before each visit, in order to assess 
sodium excretion. Plasma renin activity and plasma angiotensin II concentrations 
were assessed following dietary modifications prior to the beginning of each study 
visit. At each visit subjects had local and systemic cardiovascular studies performed. 
All subjects abstained from alcohol and caffeine for 24 hours and food from 4 hours 
prior to their study visit. All studies were performed in a quiet, temperature 
controlled room maintained at 22-24°C with subjects lying supine. There was 
minimal mobilisation between the local and systemic vascular studies. 
 
Protocol 1: 
All subjects underwent brachial artery cannulation with a 27-standard wire gauge 
steel needle under aseptic conditions. After a 30-minute baseline 0.9% saline 
infusion, forearm blood flow was assessed following intra-arterial infusion of 
(Pyr1)apelin-13 (0.3, 1.0 and 3.0 nmol/min), acetylcholine (5, 10 and 20 µg/min) and 
sodium nitroprusside (0.5, 1.0 and 2.0 µg/min) given in a double blind randomised 
manner, [Japp et al 2008] with each infusion given for 6 minutes (Figure 3.1). 
Dosages of intra-arterial (Pyr1)apelin-13 were determined from previous studies 
within our group [Japp et al 2008; Japp et al 2010]. The sequence of vasodilator 
administration was randomised between subjects but was kept constant for each 
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individual subject, in order to maintain a consistent order for both study visits, with 
30-minute saline infusions separating each vasodilator.  
 
Forearm blood flow was measured in the infused and non-infused arms by venous 
occlusion plethysmography, as described previously [Newby et al 1997a). Supine 
heart rates and blood pressure were measured in the non-infused arm at regular 
intervals during the study.  
 
Protocol 2:  
Cardiac index, peripheral vascular resistance, mean arterial pressure and heart rate 
were measured every 5 minutes during a 0.9% saline infusion using thoracic 
impedance cardiography and a semi-automated non-invasive sphygmomanometer, as 
described previously [Thomas 1992]. Once all readings were within 10% of a rolling 
average and only after a minimum of a 30-minute run-in infusion, cardiac index, 
peripheral vascular resistance, mean arterial pressure and heart rate were measured 
during systemic (Pyr1)apelin-13 infusion (30, 100 and 300 nmol/min) or placebo, 
administered for 6 minutes (Figure 3.2). (Pyr1)apelin-13 and placebo infusion were 
separated by a 30-minute washout period. Infusions were administered in a 
randomised double blinded manner. The dose of (Pyr1)apelin-13 was determined 
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Figure 3.2.  Study protocol for the systemic haemodynamic studies. 
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Figure 3.1 Study design for local vascular studies 
Figure 3.2 Study design for systemic haemodynamic studies 
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3.3.3  DATA AND STATISTICAL ANALYSIS  
Variables are reported as mean±SEM and analysed using repeated measures 
ANOVA with post-hoc Bonferroni corrections and paired two-tailed Student’s t-test 
as appropriate (GraphPad Prism). Forearm blood flow was calculated from 
plethysmographic data, as described previously [Newby et al 1998; Japp et al 2008]. 
Mean arterial pressure was defined as the sum of the diastolic blood pressure and a 
third of the pulse pressure. Peripheral vascular resistance index was calculated as 
mean arterial pressure minus mean right atrial pressure, divided by cardiac index. 
Statistical significance was taken as P <0.05. Based on power calculations derived 
from previous studies [Japp et al 2010] and a significance level of 5%, the sample 
sizes (n=12) will give 90% power of detecting the clinically meaningful differences 
of 0.7 mL/100 mL per minute and 0.6 L/min in forearm blood flow and cardiac 
output, respectively. We have previously described the influence of a range of factors 
on regional and systemic vascular beds using sample sizes of 8 to 12 subjects. (Japp 














3.4.1  STUDY PARTICIPANTS 
Healthy volunteers were male, aged 21±0 years with a body mass index of           
22±1 kg/m2. All studies were well tolerated and progressed without any serious 
adverse events. 
 
3.4.2  RENIN-ANGIOTENSIN SYSTEM ACTIVATION: SODIUM DEPLETION 
Subjects adhered to the sodium depleted diet (Appendix, p 186), as demonstrated by 
a marked reduction in urinary sodium excretion (34±6 versus 175±21 mmol/day; 
P <0.0001) and increases in both plasma renin activity (4.2±0.9 versus              
0.8±0.2 ng/mL/hr; P <0.01) and plasma angiotensin II concentrations 













































































Figure 3.3.  A) Total 24-hour urinary sodium excretion (mmol) during sodium replete diet (blue) or 
sodium depleted diet. B) Plasma renin activity (PRA) (ng/mL/hr) during sodium replete diet (blue) or 
sodium deplete diet (red). C) Plasma angiotensin II concentrations (pg/mL) during sodium replete diet 





















































3.4.3		PERIPHERAL RESISTANCE VESSELS 
Local APLNR agonism was assessed with (Pyr1)apelin-13 (Genscript). There were 
no changes in heart rate, blood pressure or non-infused forearm blood flow 
throughout all the studies.  
 
Baseline forearm blood flow was unchanged by sodium depletion (1.9±0.2 versus 
1.9±0.2 mL/100 mL/min; P >0.05). Both (Pyr1)apelin-13 and sodium nitroprusside 
caused vasodilatation in the infused arm (P <0.001 for all), and these responses were 
similar under both dietary conditions (P >0.05 for sodium deplete versus 
sodium replete diet; Figure 3.4). Acetylcholine caused dose-dependent vasodilatation 
under both dietary conditions (P <0.001 for all), and was attenuated, but not 
abolished, during sodium depletion (P <0.001, sodium deplete versus 











































Figure 3.4.  A) Sodium replete diet: forearm blood flow (mL/100mL/min) during intra-arterial 
(Pyr1)apelin-13 (blue circles, top), acetylcholine (blue triangles, middle) or sodium nitroprusside (blue 
squares, bottom). *P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA with post-hoc Bonferroni 
test. B) Sodium deplete diet: forearm blood flow (mL/100mL/min) during intra-arterial (Pyr1)apelin-
13 (red circles, top), acetylcholine (red triangles, middle) or sodium nitroprusside (red squares, 
bottom). P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA with post-hoc Bonferroni test.           
C) Comparison of sodium replete (blue, all) and sodium deplete (red, all) diets. Forearm blood flow 
(mL/100mL/min) during intra-arterial (Pyr1)apelin-13 (circles, top), acetylcholine (triangles, middle) 
or sodium nitroprusside (squares, bottom). *P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA 
with post-hoc Bonferroni test. ANOVA - analysis of variance. 
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3.4.4  SYSTEMIC APLNR AGONISM 
Systemic APLNR agonism was assess with (Pyr1)apelin-13 (Genscript). Baseline 
haemodynamic data are presented in Table 3.1, with no differences observed at 
baseline. Intravenous (Pyr1)apelin-13 infusion increased cardiac index (P <0.001 for 
both), reduced mean arterial pressure (P <0.02 for both) and reduced peripheral 
vascular resistance index (P <0.001 for both) compared to matched placebo with no 
differences between the sodium deplete and sodium replete diets (Figure 3.5). A 
trend to increased heart rate was evident following the sodium replete diet (P=0.06) 
that was not present during sodium depletion. In keeping with our previous work 
[Japp et al 2010], (Pyr1)apelin-13 rapidly achieved its peak systemic haemodynamic 






TABLE 3.1   Baseline  haemodynamic data 
  Sodium replete diet 
Sodium 
deplete diet  
Cardiac Index                                     
L/min/m2 4.0±0.2 4.1±0.3 
Heart Rate                                                
beats/min 60.8±2.6 62.3±4.0 
Systolic Blood Pressure                          
mmHg 128.4±4.9 124.8±3.1 
Diastolic Blood Pressure                         
mmHg 72.3±2.7 70.0±1.4 
Mean Arterial Pressure                         
mmHg 89.9±2.9 88.2±1.6 
Peripheral Vascular Resistance Index   
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Figure 3.5.  A) Sodium replete diet: Percentage change from baseline in cardiac index, heart rate, 
mean arterial pressure and peripheral vascular resistance during intravenous (Pyr1)apelin-13 (blue 
circles, closed) or placebo (black circles, open. *P <0.05, **P <0.01, ***P <0.001. Two-way 
ANOVA with post-hoc Bonferroni test. B) Sodium deplete diet: Percentage change from baseline in 
cardiac index, heart rate, mean arterial pressure and peripheral vascular resistance during intravenous 
(Pyr1)apelin-13 (red squares, closed) or placebo (black squares, open). *P <0.05, **P <0.01, ***P 
<0.001. Two-way ANOVA with post-hoc Bonferroni test. C) Comparison of sodium replete (blue, 
all) and sodium deplete (red, all) diets: Percentage change from baseline in cardiac index, heart rate, 
mean arterial pressure and peripheral vascular resistance during intravenous (Pyr1)apelin-13 (blue 
squares closed, sodium replete diet; red squares, closed, sodium deplete) . *P <0.05, **P <0.01, 
***P <0.001. Two-way ANOVA with post-hoc Bonferroni test.  




3.5      DISCUSSION 
 
This is the first study in man to assess the effect of APLNR agonism under 
conditions of subacute renin-angiotensin activation. During these studies the local 
and systemic effects of APLNR agonism were preserved and, as such, the effect of 
(Pyr1)apelin-13 are predicted to retain their efficacy under conditions of renin-
angiotensin system upregulation. No physiologically relevant interaction between 
these two hormone systems was identified in these studies.  
 
In this study there was good adherence to the sodium depleted diet, as reflected by 
changes in sodium excretion (34±6 versus 175±21 mmol/day; P <0.0001), with 
corresponding upregulation of the renin-angiotensin system demonstrated by 
increased plasma renin activity (4.2±0.9 versus 0.8±0.2 ng/mL/hr; P <0.01) and 
plasma angiotensin II concentrations (11.6±1.9 versus 5.1±1.0 pg/mL; P <0.01) 
compared to the sodium  replete diet. Therefore, the lack of interaction, we feel, does 
not reflect insufficient upregulation of the renin-angiotensin system. Furthermore, 
the timescale and extent of renin-angiotensin system activation are sufficient to alter 
apelin-APLNR expression. Preclinical data suggest that angiotensin II results in 
apelin downregulation within 24 hours, even at subpressor doses [Iwanaga et al 
2006].  
 
In contrast to (Pyr1)apelin-13, acetylcholine-induced vasodilatation was impaired 
following sodium depletion and renin-angiotensin system activation, suggesting the 
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presence of endothelial dysfunction. In vitro angiotensin II promotes superoxide 
anion generation when incubated with vascular smooth muscle cells [Griendling et al 
1994]. Furthermore, in whole animals treated with angiotensin II, superoxide 
generation is increased and vasorelaxation to acetylcholine is impaired [Rajagopalan 
et al 1996]. The effect of dietary sodium on endothelial function has previously been 
assessed in both healthy individuals and patient populations [Stein et al 1995; 
Miyoshi et al 1997; Higashi et al 2001; Omland et al 2001; Tzemos et al 2008], 
which has led to diverse findings, with some investigators reporting the induction of 
vascular dysfunction with sodium loading [Miyoshi et al 1997] and no effect of 
sodium depletion [Higashi et al 2001; Omland et al 2001]. This appears to reflect the 
incorporation of differing patient groups, such as those with hypertension        
[Higashi et al 2001], with prolonged renin-angiotensin activation and alterations in 
vascular function dominated by factors other than those seen in short term dietary 
manipulation.  
 
There is growing evidence of an interaction between the apelin-APLNR and renin-
angiotensin systems that extends beyond their opposing physiological actions. The 
transcription of apelin is reduced under conditions of angiotensin II elevation 
[Iwanaga et al 2006], which is evident within 24 hours and at subpressor doses. In       
preclinical models of vascular smooth muscle, transcription of the AT1R can be 
inhibited by ATRA. When hypertensive rats, which have elevated renin-angiotensin 
system activity, are treated with ATRA there is an elevation in APLNR expression, 
an increase in plasma nitrates and a fall in blood pressure, accompanied by a 
reduction in AT1R expression [Zhong et al 2005]. Whilst not assessed in a single 
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study, mechanical stretch reduces APLNR expression within 24 hours [Szokodi et al 
2002] and other groups report an increase in the AT1R in similar models over a 
similar time frame [Kijima et al 1996]. These data suggest that the transcriptions of 
the AT1R and APLNR expression are closely related. 
 
In knockout animal studies, the interaction of the apelin-APLNR system has been 
investigated, and it appears that the APLNR modifies vascular responses to 
angiotensin II; in APLNR-deficient animal models there is an exaggerated pressor 
response to angiotensin II, whilst double AT1R and APLNR knockout animals have 
elevated blood pressure relative to AT1R-deficient mice [Ishida et al 2004]. 
However, we have demonstrated that the haemodynamic cardiovascular effects of 
apelin are preserved in the presence of subacute renin-angiotensin system activation. 
This suggests that there does not appear to be a major functional interaction in vivo 
in man although we cannot exclude such an interaction in other settings. 
 
3.5.1  LIMITATIONS 
No evidence of an interaction between these two systems has been identified in the 
sub-acute setting. Whilst we do not believe the study was underpowered, it is 
possible that an interaction is present but below the limits of detection by the 
techniques used; alternatively, it may be sufficiently small that more individuals 
would need to be studied.  
 
The extent of renin-angiotensin II activation was assessed on the third day through 
plasma renin-activity, plasma angiotensin II concentrations and urinary sodium 
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excretion, and we believe that on the day of study we achieved sufficient renin-
angiotensin activation. We assumed that upregulation in renin-angiotensin activity 
would impact sufficiently on apelin-APLNR activity and expression, and crucially 
this serves to model diseases that are characterised by renin-angiotensin activity, 
such as heart failure. What is less clear from these studies is the tissue expression and 
activity of the APLNR and AT1R; there would have been no easy method available 
to quantify this. Preclinical evidence supports the role of increased AT1R expression 
in response to elevated angiotensin II, and this may have been relevant [Cheng et al 
1995]. 
 
There is a finite time period that permits adherence to the strict dietary protocol 
required for renin-angiotensin system activation. The aim of this particular protocol 
was to assess the interaction between the renin-angiotensin system and the apelin-
APLNR system over a period that we believed would be sufficient to modify apelin-
APLNR system downregulation, and we believe that this protocol addressed that 
hypothesis. It is possible that these two systems may interact over a longer duration, 
and evidently this possibility has not been addressed by the present study.  
 
Additionally, changes in the renin-angiotensin axis and alterations in dietary sodium 
may have impacted upon other hormone systems, notably vasopressin release. Both 
preclinical and clinical studies have highlighted that apelin release is related to 
vasopressin release [Azizi et al 2008], and there appears to be a reciprocal 
relationship between these two hormone systems. However, it is impossible in vivo 
in humans to alter one hormone system in isolation. Furthermore, upregulating the 
	 93 
renin-angiotensin system, as we did in this protocol, may more accurately reflect 
heart failure, which exhibits an over activation of several hormone systems     
[Rouleau et al 1991; Rouleau et al 1993; Kirlin et al 1995]. 
 
In summary, the cardiovascular effects of (Pyr1)apelin-13 are preserved during 
subacute renin-angiotensin activation and there does not appear to be a significant 
physiological interaction between these two systems over the time period 
investigated. From these studies, we predict that the apelin-APLNR system will 
retain efficacy in chronic stable heart failure, while the APLNR is an attractive 








CHAPTER  4 
 
LOCAL AND SYSTEMIC VASCULAR RESPONSES TO  
APELIN RECEPTOR AGONISM DURING  
ACUTE ANGIOTENSIN II INFUSION 
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4.1 SUMMARY  
 
Introduction   In preclinical models (Pyr1)apelin-13 reverses angiotensin II 
vasoconstriction. However, some studies report increased angiotensin II signalling in 
the presence of APLNR activation. The aim of this study was to assess the local and 
systemic vascular response to (Pyr1)apelin-13 infusion during acute angiotensin II 
infusion.  
 
Methods   Forearm blood flow was assessed with venous occlusion 
plethysmography during intra-arterial (Pyr1)apelin-13 (0.3, 1.0 and 3.0 nmol/min), or 
sodium nitroprusside (2.0, 4.0 and 8.0 µmol/min), administered in a randomised 
double blinded design, during background angiotensin II infusion, which was titrated 
to reduce baseline forearm blood flow by ~50%. Thereafter, on different study visits 
separated by at least one week, participants were randomised in a crossover 
double blinded design to systemic subpressor angiotensin II (0.5 µg/kg/min) or a 
placebo (0.9% saline), with cardiac index, systemic vascular resistance index, heart 
rate and mean arterial pressure assessed by thoracic electrical bioimpedance and a 
semi-automated sphygmomanometer respectively during systemic (Pyr1)apelin-13 
infusion (30, 100 and 300 nmol/min) and placebo (0.9% saline) administered in a 
double blinded randomised design. 
 
Results   Local vasodilator effect of intra-arterial (Pyr1)apelin-13 was retained 
following angiotensin II vasoconstriction. Similarly, the systemic response to 
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intravenous (Pyr1)apelin-13 infusion was unaffected by co-administration of the 
systemic angiotensin II infusion.  
 
Conclusion   Local and systemic actions of (Pyr1)apelin-13 are unaffected by acute 
angiotensin II infusion. There are no data from this study to support the hypothesis 
that APLNR agonism potentiates AT1R response. 
 
4.2        INTRODUCTION 
 
The apelin receptor is a G protein-coupled receptor which most closely resembles the 
AT1R, as they share around a 50% sequence homology in the transmembrane 
domains and have a similar tissue location [O'Dowd et al 1993]. However, 
angiotensin II does not bind to the APLNR, and it appears that these two receptors 
mediate opposing actions on fluid balance [Azizi et al 2008], inflammation [Chun et 
al 2008] and vascular tone [Gurzu et al 2006; Zhong et al 2007a].  
 
There is increasing evidence that the APLNR and AT1R have important interactions. 
The angiotensin II type 1 receptor has been shown to form heterodimers with the 
bradykinin type 1 receptor [AbdAlla et al 2000; AbdAlla et al 2001; AbdAlla et al 
2005], and the formation of these complexes modifies monoreceptor responses. 
When the AT1R is co-expressed with the bradykinin receptor, the efficacy of 
angiotensin II signalling is increased [AbdAlla et al 2000]. Conversely, the 
expression of the angiotensin II type 2 receptor results in heterodimer formation with 
the AT1R, an interaction that inhibits angiotensin II response [AbdAlla et al 2001]. 
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These data suggest that there is vital communication between G protein-coupled 
receptors that influences cellular signalling. Given the structural and functional 
properties of apelin-APLNR and the renin-angiotensin system, interactions between 
APLNR and the AT1R have been investigated. Preclinical studies support that the 
formation of AT1R and APLNR heterodimers [Chun et al 2008; Sun et al 2011] in 
the presence of the non-activated APLNR, act to inhibit AT1R signalling [Sun et al 
2011]. 
 
In preclinical and clinical studies, APLNR activation does not appear to potentiate 
the vascular effects of angiotensin II. In rodent veins pretreated with apelin, 
angiotensin II constriction effects are reduced [Gurzu et al 2006], whilst in whole 
animal studies apelin infusion abolishes the pressor effects of angiotensin II. There 
are limited data from clinical studies specifically assessing the interaction between 
apelin-APLNR and the renin-angiotensin system. Clinical studies have been 
performed in healthy volunteers, with no manipulation of the renin-angiotensin 
system, or in patients with chronic stable heart failure [Japp et al 2010]. Studies in 
patients with chronic stable heart failure, investigating the relationship between these 
two systems, are limited by the potential for chronic activation of the renin-
angiotensin system and the fact that the patients are medicated with drugs that alter 
renin-angiotensin system activity. 
 
It is essential to determine whether any receptor interaction exists functionally          
in vivo in man. We have undertaken clinical studies in both local and systemic 
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circulation to assess the interaction between these two systems following acute 
activation of the AT1R.  
 
4.2.1  HYPOTHESIS 
We hypothesise that the local and systemic cardiovascular actions of (Pyr1)apelin-13 
will be reduced during acute angiotensin II infusion, through reduced availability of 
the APLNR, and this may even potentiate AT1R signalling. 
 
4.3     METHODS  
 
4.3.1  SUBJECTS 
Twenty-four subjects were recruited, with two groups of 12 subjects allocated to 
local and systemic studies. Each subject attended on two occasions and at least one 
week apart. All subjects abstained from alcohol and caffeine for 24 hours and from 
food 4 hours prior to their study visit. All studies were performed in a quiet, 
temperature controlled room maintained at 22-24°C, with the subjects lying supine.  
 
4.3.2  LOCAL VASCULAR STUDIES 
Twelve subjects attended on one occasion, and local vascular responses to apelin 
were assessed during acute intrabrachial angiotensin II infusion (Figure 4.1). The 
dosage of angiotensin II (5-30	pmol/min) was up titrated until forearm blood flow 
was reduced by ~50%. Once sufficient and stable vasoconstriction was achieved, 
(Pyr1)apelin-13 (0.3, 1.0 and 3.0 nmol/min) (Genscript, NJ, USA) and sodium 
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nitroprusside (2, 4 and 8 µg/min) were co-infused with angiotensin II in a 
randomised double blind manner with each administration lasting for 6 minutes.  
 
 








Sodium nitroprusside    
           (µg/min) 
(Pyr1)Apelin-13  
  (nmol/min) 
Saline (Pyr
1)Apelin-13  
  (nmol/min) 
100 300 30 Saline Saline 
Systemic Angiotensin II or Saline infusion  
1.0 3.0 0.3 Saline Saline 
Local Angiotensin II  
2.0 4.0 8.0 
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4.3.3  SYSTEMIC VASCULAR STUDIES 
In a double blind randomised crossover design, subjects received an infusion of 
intravenous angiotensin II at a subpressor dose (0.5 ng/kg/min) or a matched 0.9% 
saline placebo, as described previously [Ljungman et al 1983]. The subjects then 
received ascending doses of intravenous (Pyr1)apelin-13 (30, 100 and 300 nmol/min) 
(Genscript, NJ, USA)  or a matched saline placebo, administered for 6 minutes at 
each dose and given in a double blind randomised crossover manner [Japp et al 
2010]. The apelin and placebo administration sequence was randomised between 
subjects but was kept constant for each individual subject, in order to maintain a 
consistent order for both study visits. 
 
4.3.4  DATA AND STATISTICAL ANALYSIS  
Variables are reported as mean±SEM and analysed using repeated measures 
ANOVA with post-hoc Bonferroni corrections and paired two-tailed Student’s          
t-test as appropriate (GraphPad Prism). Forearm blood flow was calculated from 
plethysmographic data, as described previously [Newby et al 1998; Japp et al 2008]. 
Mean arterial pressure was defined as the sum of the diastolic blood pressure and a 
third of the pulse pressure. Peripheral vascular resistance index was calculated as 
mean arterial pressure minus mean right atrial pressure, divided by cardiac index. 
Statistical significance was taken as P <0.05.  Based on power calculations derived 
from previous studies [Japp et al 2010] and a significance level of 5%, the sample 
sizes (n=12) will give 90% power of detecting the clinically meaningful differences 
of 0.7 mL/100 mL per minute and 0.6 L/min in forearm blood flow and cardiac 
output, respectively. We have previously described the influence of a range of factors 
	 101 
on regional and systemic vascular beds using sample sizes of 8 to 12 subjects. (Japp 






4.4.1  STUDY PARTICIPANTS 
Healthy volunteers were male, aged 21±0 years and with a body mass index of    
22±1 kg/m2. All infusions were well tolerated, with no serious adverse events.  
 
4.4.2  LOCAL VASCULAR ACTIONS OF APELIN DURING ACUTE RENIN-ANGIOTENSIN 
ACTIVATION 
Local APLNR agonism was assessed with (Pyr1)apelin-13 (Genscript). Local intra-
arterial angiotensin II infusion caused a marked increase in local angiotensin II 
concentrations (95.6±16.0 versus 4.5±1.0 pg/mL; P <0.0001) that was accompanied 
by a reduction in forearm blood flow (from 2.5±0.4 to      
1.3±0.3 mL/100 mL/min; P=0.001) in the infused forearm. In the local 
vasoconstriction setting, both (Pyr1)apelin-13 (P=0.02) and sodium nitroprusside 
























Figure 4.2.		A) Forearm blood flow (mL/100mL/min) during intra-arterial (Pyr1)apelin-13 (blue 
circles) following pre-constriction with angiotensin II. *P <0.05, **P <0.01, ***P <0.001. One-way 
ANOVA with a post-hoc Bonferroni test. B) Forearm blood flow (mL/100mL/min) during intra-
arterial sodium nitroprusside (red squares) following pre-constriction with angiotensin II. *P <0.05, 
**P <0.01, ***P <0.001. One-way ANOVA with a post-hoc Bonferroni test. 
ANOVA - analysis of variance. 
  























































4.4.3   SYSTEMIC VASCULAR ACTIONS OF APELIN DURING ACUTE RENIN-
ANGIOTENSIN ACTIVATION  
Systemic APLNR agonism was assessed with (Pyr1)apelin-13 (Genscript). Baseline 
haemodynamic data are presented in Table 4.1. No differences were observed, at 
baseline (prior to run-in infusion) and saline run-in infusion had no effect on 
systemic haemodynamics (data not shown). Intravenous angiotensin II infusion 
(0.5 ng/kg/min) increased systemic angiotensin II concentrations (from 3.7±0.4 to 
7.3±0.8 pg/mL; P=0.001). Although it was our intention to administer a subpressor 
dose of angiotensin II [Ljungman et al 1983], we observed a small increase in both 
mean arterial pressure (from 82±1 to 86±1 mmHg; P=0.0014) and peripheral 
vascular resistance index (from 1420±80 to 1529±91 dynes.s/cm5/m2; P <0.0001), 
with a small reduction in cardiac index (from 4.6±0.2 to                 4.4±0.2 L/min/m2; 
P=0.0288) during angiotensin II infusion. Compared to placebo, angiotensin II 
infusion had no increasing effect on cardiac index or a reducing effect on mean 
arterial pressure or peripheral vascular resistance index observed during systemic 
(Pyr1)apelin-13 infusion (ANOVA; P >0.05, Figure 4.3). There appeared to be an 
initial increase in heart rate following apelin infusion (ANOVA; P <0.02) during 







TABLE 4.1   Baseline and post run-in systemic haemodynamics 
 Angiotensin II infusion baseline 
Angiotensin II 
infusion run-in  
Saline 
infusion 
Cardiac Index                                  
L/min/m2 4.6±0.2 4.4±0.2 4.4±0.2 
Heart Rate                                                
beats/min 57.4±1.9 58.9±2.1 55.4±2.3 
Mean Arterial Pressure                    
mmHg 82.4±1.1 86.2±4** 82.4±1.6 
Peripheral Vascular Resistance Index            
dynes.s/cm5/m2 1420±80.0 1534±97 1479±870 
 
   Paired Student’s t-test, angiotensin baseline versus run-in. 






Figure 4.3.  A) Background saline infusion; percentage change in cardiac index, mean arterial pressure, 
peripheral vascular resistance index and heart rate during systemic infusion of (Pyr1)apelin-13 (blue circles, 
closed) or saline (black circles open) *P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA with post-hoc 
Bonferroni test. B) Background angiotensin II infusion; percentage change in cardiac index, mean arterial 
pressure, peripheral vascular resistance index and heart rate during systemic infusion of  (Pyr1)apelin-13 (red 
squares, closed) or saline (black squares,  open). *P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA with 
post-hoc Bonferroni test. C) Comparison of background infusions, saline or angiotensin II; percentage change in 
cardiac index, mean arterial pressure, peripheral vascular resistance index and heart rate during systemic infusion 
of  (Pyr1)apelin-13 during placebo infusion (blue circles, closed) or angiotensin II infusion (red squares, closed). 
*P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA with post-hoc Bonferroni test. 
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In these studies we have shown for the first time in man that the local and systemic 
cardiovascular actions of acute (Pyr1)apelin-13 infusions are unaffected by acute 
angiotensin II elevation and APLNR signalling persists in the presence of AT1R 
activation.  
 
Angiotensin II infusions resulted in 21-fold and 2-fold increases in local and 
systemic plasma angiotensin II concentrations, respectively. During local vascular 
studies, local forearm blood flow was reduced by ~50%, and in systemic studies, 
although the protocol was designed to administer a subpressor dose of angiotensin II, 
pressor effects during systemic infusion were evident. Whilst the blood pressure 
elevations observed were of questionable biological significance, the changes in 
mean arterial pressure were of statistical significance. In all phases of the study, we 
successfully achieved a range of renin-angiotensin systemic activation, and we do 
not believe that the lack of effect is due to a failure to augment plasma angiotensin II 
concentrations. 
 
Accumulating evidence suggests acute interactions between the apelin-APLNR 
system and the renin-angiotensin system and, in particular, the interaction between 
the AT1R and the APLNR [Chun et al 2008; Sun et al 2011]. In cellular models, the 
AT1R has been shown to form heterodimers with other G protein-coupled receptors 
[AbdAlla et al 2000; AbdAlla et al 2001; AbdAlla et al 2005; Li et al 2012]. These 
interactions are reported to have important functional consequences in preclinical 
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studies as they alter the activity of intracellular signalling cascades and receptor 
metabolism. Formation of heterodimers can result in exaggerated angiotensin II 
effects, as seen with the angiotensin type 1 receptor-bradykinin B2 heterodimer 
complexes [AbdAlla et al 2000; AbdAlla et al 2005], or dampened responses, as 
with angiotensin type 2 receptors [AbdAlla et al 2001]. 
 
Preclinical studies investigating the functional consequences of APLNR-AT1R 
heterodimers have shown that this complex inhibits angiotensin II actions. Sun et al 
[2011] reported that in the presence of the inactive APLNR receptor, angiotensin II 
signalling was inhibited as a result of heterodimer formation, and with the addition of 
apelin to this cellular model, angiotensin II signals were enhanced. This suggests that 
ligand binding to APLNR prevents dimerisation and angiotensin II inhibition, which 
implies that the APLNR in its basal form functions to antagonise AT1R signalling. In 
this study there was no evidence of a potentiated angiotensin II response with 
(Pyr1)apelin-13 infusion. Whilst Chun et al [2008], who first reported the formation 
of an APLNR-AT1R heterodimer, report the inhibition of angiotensin II-mediated 
signals in the presence of the APLNR, there was no enhancement of angiotensin II 
effects in the presence of activated APLNR. 
 
It must be acknowledged that evidence of heterodimerisation is limited to preclinical 
studies and often in cellular constructs, which may not accurately reflect receptor 
interaction in tissues in vivo in humans. Furthermore, this phenomenon does not 
appear to be universal, with studies reporting no evidence of                             
angiotensin type 1 receptor-bradykinin B2 receptor heterodimer complexes in a 
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range of models, which questions the functional relevance of this suggested 
interaction [Hansen et al 2009]. 
 
4.5.1  LIMITATIONS 
No evidence of an interaction between these two systems has been identified in the 
acute setting. From preclinical studies we could have predicted that co-infusion of 
angiotensin II and (Pyr1)apelin-13 may result in reduced efficacy of (Pyr1)apelin-13, 
or even increase the efficacy of angiotensin II. We do not believe the study was 
underpowered, however, it is possible that an interaction is present but below the 
limits of detection by the techniques used; alternatively, it may be sufficiently small 
that more individuals would need to be studied.  
 
No control vasoconstrictor was used in this study protocol and alternative 
vasoconstrictor, such as noradrenaline, would allow some inference to a general 
vasodilator action or a more specific function to reverse angiotensin II mediated 
vasoconstriction.  
 
These studies were undertaken to assess acute interactions that may reflect direct 
receptor interactions. At present no methods are available to assess examination of 
receptor complexes and interaction in vivo. Furthermore, if heterodimer formation is 
of biological significance, it is conceivable that multiple dynamic receptor 
interactions exist which have not been fully characterised in preclinical models.  
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These studies have been performed in healthy individuals, free from cardiovascular 
disease and not receiving any regular medication. The results of the study may not be 
universal and there may be important interactions between these two systems in 
diseases such as heart failure.  
 
In summary, acute local and systemic actions of (Pyr1)apelin-13 are preserved in the 
presence of acute angiotensin II infusion. This suggests that the signalling of the 
APLNR is unaffected by angiotensin II, and that AT1R signalling is unaffected by 
(Pyr1)apelin-13. These data do not confirm any interactions between these two 
systems during the investigated period; however, we cannot exclude the possibility 
that an interaction does exist or that these two systems may have important 
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Acute cardiovascular effects of apelin in humans: potential role 




5.1 SUMMARY  
 
Introduction   In preclinical studies the apelin-APLNR systems maintain cardiac 
contractile function, whilst exogenous apelin is a potent inotrope. Furthermore in 
heart failure models the apelin-APLNR system is downregulated suggesting a 
pathophysiological role, but raises concerns of tachyphylaxis. The aim of this study 
was to assess the safety and cardiovascular effects of systemic (Pyr1)apelin-13 
infusion.  
 
Methods   Eight patients with chronic stable heart failure attended on two visits, at 
least one week apart. Cardiac index, systemic vascular resistance index, heart rate 
and mean arterial pressure assessed by thoracic electrical bioimpedance and a semi-
automated sphygmomanometer respectively during systemic (Pyr1)apelin-13 infusion 
(30, 100 and 300 nmol/min) or placebo (0.9% saline) in a randomised double blinded 
crossover design.  
 
Results   Acute (Pyr1)apelin-13 infusion resulted in increased cardiac output and a 
reduction in mean arterial pressure during acutely systemic (Pyr1)apelin-13 infusion 
(P <0.05). 
 
Conclusion   The cardiovascular effects of exogenous (Pyr1)apelin-13 are preserved 
in patients with chronic stable heart failure. These data support the role of APLNR 
agonism in chronic stable heart failure, and suggest that there is sufficient 
	 112 
myocardial APLNR density to evoke a meaningful response. Longer term studies are 




The apelin receptor is expressed in high quantities in the myocardium [Kleinz and 
Davenport 2004] and functions as a positive inotrope. In isolated cardiomyocytes, 
apelin is reported to be the most potent inotrope studied in vitro and is effective at 
subnanomolar concentrations [Farkasfalvi et al 2007]. Similarly, in paced atrial 
strips, there is a dose-dependent contractile effect at subnanomolar concentrations 
[Maguire et al 2009]. In perfused hearts [Berry et al 2004] and whole animal studies, 
APLNR agonism mediates positive inotropic effects, independent of cardiac loading 
conditions and without inducing left ventricular hypertrophy [Ashley et al 2005]. 
Initial clinical studies in healthy volunteers are in agreement with preclinical studies, 
and exogenous (Pyr1)apelin-13 infusion mediates positive inotropism [Japp et al 
2008]. 
 
The apelin-APLNR system has an important role in maintaining normal cardiac 
function. Whilst apelin-deficient mice have normal cardiovascular development, they 
progress to heart failure with age and increased afterload [Kuba et al 2007]. 
Furthermore, apelin-deficient rodents have a reduced fractional shortening and    
end-systolic pressure volume relationship at baseline, along with impaired 
ventricular performance during stress. Equally, exercise ability of rodents in reduced 
in either rodents deficient in apelin or the APLNR [Charo et al 2009].  
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Given the cardiovascular actions of exogenous apelin, and the requirement of the 
apelin-APLNR system to maintain normal cardiac function, the apelin-APLNR 
system has been investigated in ventricular dysfunction, in both preclinical and 
clinical studies. In cardiomyocytes exposed to repetitive stretch, analogous to volume 
overload in ventricular dysfunction, there is rapid downregulation of APLNR 
expression [Szokodi et al 2002]. Additionally, in hypertensive models of heart 
failure, as left ventricular dysfunction ensues there is downregulation of both cardiac 
apelin and APLNR expression [Iwanaga et al 2006].  
 
In man, there are limited data regarding cardiac apelin expression. However, in 
patients with left ventricular dysfunction of idiopathic aetiology, APLNR 
downregulation is evident [Földes et al 2003; Pitkin et al 2010]. Furthermore, in 
patients undergoing heart transplantation, who are treated with left ventricular assist 
devices prior to surgery, apelin is the most upregulated gene in the myocardium 
[Chen et al 2003]. 
 
The utility of circulating apelin as a biomarker has been assessed in patients with 
ventricular dysfunction. An initial increase in plasma apelin circulation has been 
reported in early heart failure, suggesting a compensatory role, with a reduction in 
more severe heart failure, suggesting the requirement of apelin to maintain normal 
cardiac function [Chen et al 2003]. However, others have failed to demonstrate any 
relationship between the extent of ventricular dysfunction and plasma concentration 
beyond a reduction in heart failure [Chong et al 2006].  
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Taken together, these data support a role for the apelin-APLNR system in 
maintaining normal cardiac function and show downregulation in heart failure, 
suggesting a pathophysiological role. Characterising the action of apelin in heart 
failure is essential to explore any therapeutic benefit of this system. 
 
5.2.1  HYPOTHESIS 
Systemic infusion of (Pyr1)apelin-13 in patients with chronic stable heart failure will 
result in an increase in cardiac output and reduction in both mean arterial pressure 




Eight patients with chronic stable heart failure were recruited and attended on one 
occasion. Patients were eligible for inclusion if they had chronic stable heart failure 
and were in NYHA class II-IV, receiving maximally tolerated doses of heart failure 
medication for at least 3 months and had evidence of left ventricular dysfunction on 
echocardiography examination (left ventricular end-diastolic diameter >5.5 cm, left 
ventricular ejection fraction <40% or fractional shortening <20%). Patients were 
excluded if they fulfilled any of the following exclusion criteria: valvular heart 
disease, significant renal or hepatic failure, women of child-bearing potential not on 
adequate contraception or previous malignant arrhythmias. On the day of the study, 
the patients withheld their usual medication and were asked to abstain from alcohol 
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and caffeine for 24 hours and food for 4 hours. All studies were performed in a quiet, 
temperature controlled room. 
 
5.3.1   HAEMODYNAMIC STUDIES 
17-gauge cannulas were inserted into the large antecubital fossa veins in each arm, 
allowing for drug infusion and venous sampling. Blood pressure and heart rate were 
recorded with a semi-automated sphygmomanometer while mean arterial pressure 
was calculated as diastolic blood pressure plus one-third pulse pressure. Cardiac 
output was measured using HOTMAN thoracic bioimpedance and corrected for body 
surface area to derive cardiac index. Peripheral vascular resistance index was 
calculated as mean arterial pressure minus mean right atrial pressure, divided by the 
cardiac index. The electrocardiograph was recorded continuously during each study 
(Figure 5.1). Cardiac index, peripheral vascular index, mean arterial blood pressure 
and heart rate were measured during systemic (Pyr1)apelin-13 infusion (30, 100, 300 
nmol/min) (Clinalfa AG, Läufelfingen, Switzerland) or placebo infusion, 
administered for 6 minutes. (Pyr1)apelin-13 infusion and placebo infusions were 
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300 
 









5.3.2 DATA AND STATISTICAL ANALYSIS 
Variables are reported as mean±SEM and analysed using repeated measures 
ANOVA with post-hoc Bonferroni corrections and paired two-tailed Student’s t-test 
as appropriate (GraphPad Prism). Mean arterial pressure was defined as the sum of 
the diastolic blood pressure and a third of the pulse pressure. Peripheral vascular 
resistance index was calculated as mean arterial pressure minus mean right atrial 
pressure, divided by the cardiac index. Statistical significance was taken as P <0.05.  
For 80% power at 2-sided P 0.05 and based on our previously published data  a 






5.4 RESULTS  
 
5.4.1  PATIENT CHARACTERISTICS 
Table 5.1 shows baseline characteristics and current therapy. Patients were all male 
with poor contractile function assessed by echocardiography. These patients were 
maintained evidence based therapies, with only one patient not prescribed renin-
angiotensin inhibition/antagonism. 
 
TABLE 5.1   Baseline characteristics of patients with chronic stable heart failure 
Baseline Characteristics 
 
Age (Yrs)        55±4 
 
Sex (Male/Female)       8/0 
 
Aetiology (Ischaemic/Idiopathic)     5/3 
 




    Left Ventricular End-diastolic Diameter (cm)    6.5±0.5 




    β-blockade        8/8 
    Angiotensin-converting Enzyme Inhibitor/ 
       Angiotensin Receptor Blocker     7/8 






5.4.2  SYSTEMIC (PYR1)APELIN-13 INFUSION: SAFETY 
No adverse events were observed during apelin administration, and apelin infusion 
was tolerated in all subjects. No arrhythmias were induced throughout infusion.  
 
5.4.3  SYSTEMIC (PYR1)APELIN-13 INFUSION: EFFICACY 
Systemic APLNR agonism was assessed with (Pyr1)apelin-13 (Clinalfa). Intravenous 
(Pyr1)apelin-13 infusion increased cardiac index (P <0.01 for both), reduced mean 
arterial pressure and reduced peripheral vascular resistance index      (P <0.001 for 
both) in patients with chronic stable heart failure. No linear dose response was 




































Figure 5.2.  Percentage change from baseline in cardiac index, mean arterial pressure, peripheral 
vascular resistance and heart rate during intravenous (Pyr1)apelin-13 (blue circles, closed) or placebo 
(black circles, open) (blue squares, bottom). Grey bars show (Pyr1)apelin-13 infusions, 
mmol/min.*P <0.05, **P <0.01, ***P <0.001. Two-way ANOVA with post-hoc Bonferroni test. 

































































5.5 DISCUSSION  
 
This is the first study administering systemic (Pyr1)apelin-13 to patients with chronic 
stable heart failure, and it resulted in an increased cardiac index and reduced 
afterload. These data are in keeping with preclinical models and clinical studies in 
healthy volunteers. 
 
5.5.1  SAFETY 
All studies of (Pyr1)apelin-13 were well tolerated, with no adverse effects recorded. 
Of particular importance, no arrhythmias were recorded during these studies. 
 
5.5.2  EFFICACY 
In these studies, (Pyr1)apelin-13 increased cardiac index by around 10% in patients 
with chronic stable heart. These results are encouraging and suggest that the APLNR 
may be a promising target in ventricular dysfunction.  
 
There are data supporting downregulation of the apelin-APLNR system in heart 
failure [Szokodi et al 2002; Chen et al 2003; Földes et al 2003; Chong et al 2006; 
Iwanaga et al 2006; Francia et al 2007; Pitkin et al 2010]. In isolated cardiomyocytes 
exposed to repeated stretching over 24 hours, analogous to dilated heart failure, the 
APLNR is downregulated [Szokodi et al 2002]. In whole animal hypertensive heart 
failure models the apelin-APLNR system becomes downregulated as heart failure 
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ensues [Iwanaga et al 2006]. There are limited data in man regarding myocardial 
apelin-APLNR expression, but the APLNR is downregulated in dilated 
cardiomyopathy [Földes et al 2003; Pitkin et al 2010]. Furthermore, plasma 
concentrations of apelin are reduced in patients with heart failure [Chen et al 2003; 
Földes et al 2003; Chong et al 2006; Francia et al 2007]. 
 
It is proposed that downregulation in the apelin-APLNR system may contribute to 
ventricular dysfunction although, this raises concerns regarding insufficient APLNR 
density to evoke a signal. In this study we have shown that during acute infusion, 
exogenous (Pyr1)apelin-13 increases cardiac output in patients with chronic stable 
heart failure. The echocardiographic features of this cohort are consistent with severe 
ventricular dysfunction with a mean ejection fraction of around 20% and dilated   
end-diastolic diameters. It is likely that myocardial APLNR expression will be 
reduced in this cohort, and the effects that have been observed are representative of 
patients with heart failure. Furthermore, the patients recruited for this study were 
maintained on evidence-based therapies, and therefore the improvement in systemic 
haemodynamics during (Pyr1)apelin-13 infusion represents an incremental benefit. 
 
The underlying mechanism mediating the increased cardiac output observed in this 
study has not been determined. It is possible that there is a direct inotropic effect on 
the myocardium, however this may be a response to vasodilatation. A reduction in 
afterload will make some contribution, but preclinical data show direct effects of 
apelin on the myocardium [Szokodi et al 2002; Farkasfalvi et al 2007], and in whole 
animals increased cardiac output is seen during fixed preload [Berry et al 2004]. In 
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patient studies, performing pressure volume loads to assess myocardial contractility 
would be both technically and ethically challenging. 
 
The dose-response relationship shows rapid plateau suggesting that APLNR 
signalling may be fatigued easily or that it quickly reaches maximal response. 
Further work is therefore required to assess the utility of exogenous (Pyr1)apelin-13 
with prolonged APLNR activation. Although presently the acute effects are 
encouraging, it is essential to understand whether these effects are restricted to the 
acute setting or if more sustained responses are possible. There is no oral preparation 
available at present, which limits the study of chronic APLNR agonism, thus making 
an assessment on ventricular remodelling or prognosis impossible. Preclinical studies 
support a role for apelin in preventing cardiac fibrosis [Siddiquee et al 2011] and 
renin-angiotensin inhibition [Sun et al 2011]; consequently, the true value of the 
apelin-APLNR system may extend beyond its haemodynamic properties. 
 
5.5.3  LIMITATIONS 
The duration of infusion was brief, at around 20 minutes in total, and the number of 
patients included was small. Whilst the duration of infusion is appropriate in 
investigational studies, it represents a brief timescale in the context of heart failure. 
Therefore, these data are not informative when considering long term therapeutic 
benefits. Encouragingly, though, no adverse events were recorded during this study, 
however using positive inotropes in heart failure may promote arrhythmias and given 
the small number of patients studied, we cannot exclude this concern.  
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In conclusion, this study is the first to profile the cardiovascular actions of exogenous 
(Pyr1)apelin-13 in patients with chronic stable heart failure. We have demonstrated 
that acute infusions are safe, with no adverse events recorded, and APLNR 
stimulation mediates increased cardiac output. The apelin-APLNR system merits 










CHAPTER  6 
 
INVESTIGATING THE CARDIOVASCULAR EFFECTS OF  
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Introduction   In humans, plasma apelin concentrations and ventricular APLNR 
expression are reduced in heart failure. Apelin infusion has a favourable 
cardiovascular profile, although clinical trials have currently been limited to short 
15-minute infusions and there are major concerns regarding tachyphylaxis. The aim 
of this study was to assess the systemic cardiovascular response to (Pyr1)apelin-13 
infusion over 6 hours in healthy volunteers and patients with chronic stable heart 
failure.  
 
Methods   Twelve healthy volunteers and 12 patients with chronic stable heart 
failure were recruited and received systemic (Pyr1)apelin-13 (30 nmol/min) infusion 
or a placebo in a double blinded crossover design. Cardiac index, peripheral vascular 
resistance index, heart rate and mean arterial pressure were assessed using thoracic 
electrical bioimpedance and semi-automated sphygmomanometer. Left ventricular 
dimensions were assessed in patients with chronic stable heart failure at 15-minute 
intervals with echocardiography.  
 
Results   In both healthy volunteers and patients with chronic stable heart failure, 
systemic (Pyr1)apelin-13 infusion resulted in increased cardiac output throughout the 
first hour and was sustained over 6 hours. In patients with chronic stable heart failure, 
improvements in contractile indices were seen with echocardiography. No adverse 
events were seen in either the healthy volunteers or patients during (Pyr1)apelin-13 
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infusion. This study provides important information regarding the APLNR as a 
therapeutic target.  
 
Conclusion   (Pyr1)apelin-13 infusion produced a sustained effect during the 
infusion process, with no evidence of tachyphylaxis, suggesting that the APLNR 




First identified in 1993 [O'Dowd et al 1993], the APLNR is widely expressed 
throughout the body and, in particular, on the endothelium, vascular smooth muscle 
cells and cardiomyocytes [Hosoya et al 2000; Kleinz et al 2005;                   
Farkasfalvi et al 2007]. It is a G protein-coupled receptor which remained orphaned 
until its endogenous ligand apelin was discovered in 1998 [Tatemoto et al 1998]. 
Although various apelin peptide fragments exist, the pyroglutamated 13 amino acid 
form of apelin, (Pyr1)apelin-13, is the most potent and abundant form in cardiac 
tissue [Maguire et al 2009] and stimulates the APLNR to cause vasodilatation          
[Lee et al 2000; Tatemoto et al 2001] and positive inotropism [Szokodi et al 2002; 
Farkasfalvi et al 2007]. 
 
The apelin-APLNR system has an important role in maintaining cardiac function. 
Apelin-deficient animal models exhibit reduced cardiac contractility through ageing 
and severe cardiac failure in response to increased afterload [Kuba et al 2007]. 
Furthermore, apelin-deficient rodents have impaired basal ventricular function and 
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exercise tolerance [Charo et al 2009]. Expression of the APLNR is reduced in 
isolated cardiomyocytes subjected to mechanical stretch [Szokodi et al 2002] and 
animal models of heart failure [Iwanaga et al 2006]. In man, ventricular APLNR 
expression is reduced in heart failure [Földes et al 2003; Pitkin et al 2010], and there 
is therefore a concern that the effects of APLNR agonism may be abrogated or 
ineffective in patients with heart failure. Furthermore, in keeping with many            
G protein-coupled receptors [Leonard and Gulati 2009], there remains the potential 
for prolonged APLNR agonism by apelin to cause rapid desensitisation and 
tachyphylaxis, which in turn would limit the clinical utility of any potential 
therapeutic strategy targeted at chronic APLNR agonism. The dose response curve to 
APLNR agonism rapidly plateaus, which again raises concern regarding prolonged 
agonism. 
 
The role of exogenous apelin on myocardial contractility has been investigated in 
both preclinical and clinical models. In isolated myocytes apelin is a potent inotrope 
at subnanomolar concentrations [Szokodi et al 2002], and this inotropic effect is 
evident in both isolated perfused hearts and animal models. In man, systemic apelin 
infusion produces a modest increase in cardiac output [Japp et al 2010], whilst in 
heart failure, exogenous apelin increases cardiac output in preclinical models of heart 
failure [Berry et al 2004; Dai et al 2006; Atluri et al 2007] and in patients with 
chronic stable heart failure [Japp et al 2010]. There are limited data assessing 
prolonged APLNR agonism. One preclinical study demonstrated continued efficacy 
during a 2-week infusion [Ashley et al 2005], without inducing left ventricular 
	 128 
hypertrophy. However, clinical studies in heart failure are restricted to acute 
infusions [Japp et al 2010].  
 
The aims of this study were to assess the cardiovascular actions of (Pyr1)apelin-13 
during a sustained, prolonged infusion, in healthy volunteers and patients with 
chronic stable heart failure. 
 
6.2.1   HYPOTHESIS 
Prolonged systemic infusion of (Pyr1)apelin-13 in healthy volunteers and patients 
with chronic stable heart failure will result in sustained increase in cardiac output and 




6.3.1   HEALTHY VOLUNTEERS 
Twelve healthy volunteers attended on two occasions, at least one week apart, having 
been randomised in a double blinded crossover design to a systemic (Pyr1)apelin-13 
30 nmol/min (Genscript, NJ, USA) or matched saline placebo infusion (Figure 6.1). 
All studies were performed with the approval of the local Ethics Research 
Committee, in accordance with the Declaration of Helsinki and the written consent 
of all volunteers. Subjects were excluded if they were receiving any regular 
medication, had any significant past medical history, were current smokers or had 
participated in research studies within 3 months of enrolment. One participant was 
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enrolled and subsequently withdrawn, as he was found during echocardiographic 











6.3.2   PATIENTS WITH CHRONIC STABLE HEART FAILURE 
Twelve subjects with chronic stable heart failure attended on two occasions, at least 
one week apart, having been randomised in a double blinded crossover design to a 
systemic (Pyr1)apelin-13 (30 nmol/min) or matched saline placebo infusion                              
(Figure 6.1). Patients were eligible for inclusion if they had chronic stable heart 
failure and were in NYHA class II-IV, receiving maximally tolerated doses of heart 
failure medication for at least 3 months and had evidence of left ventricular 
dysfunction on echocardiography examination (left ventricular end-diastolic 
diameter >5.5 cm, left ventricular ejection fraction <40% or fractional shortening 
<20%). Patients were excluded if they fulfilled any of the following exclusion 
criteria: valvular heart disease, significant renal or hepatic failure, women of child-
bearing potential not on adequate contraception or previous malignant arrhythmias. 
Case notes for all patients under the care of the community heart failure nurse 








specialists at the Royal Infirmary of Edinburgh were reviewed. From this review, 
38 patients were contacted and received patient information sheets, in order to recruit 
12 patients to the study.  
 
All studies were performed with the approval of the local Ethics Research 
Committee, in accordance with the Declaration of Helsinki and the written consent 
of all volunteers. All studies were performed in a quiet, temperature controlled room 
maintained at 22-24°C, with the subjects lying supine.  
 
Cardiac index, peripheral vascular resistance, mean arterial pressure and heart rate 
were measured every 5	minutes during a 0.9% saline-using thoracic impedance 
cardiography and a semi-automated non-invasive sphygmomanometer, as previously 
described [Thomas 1992; Japp et al 2010]. Once all readings were within 10% of a 
rolling average, and only after a minimum 30-minute run-in infusion, cardiac index, 
peripheral vascular resistance, mean arterial pressure and heart rate were measured 
during systemic (Pyr1)apelin-13 infusion (30 nmol/min) or placebo administration 
for 6 hours. Infusions were administered in a randomised double blinded manner. 
Systemic (Pyr1)apelin-13 dosage was determined from previous studies within our 
group [Japp et al 2010]. Left ventricular end-systolic and diastolic measurements 
were assessed at baseline and at 15-minute intervals throughout the first hour of 
infusion in patient with suitable images (n=8), with fractional shortening and 
ventricular ejection fraction (Teichholz method) derived from these measurements. 
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In both health volunteer and patients with heart failure APLNR agonism was 
investigated with pharmaceutical grade (Pyr1)apelin-13 from Genscript, NJ, USA). 
 
6.3.3   DATA AND STATISTICAL ANALYSIS 
Variables are reported as mean±SEM and analysed using repeated measures 
ANOVA with post-hoc Bonferroni corrections and paired two-tailed Student’s t test 
as appropriate (GraphPad Prism). Mean arterial pressure was defined as the sum of 
the diastolic blood pressure and a third of the pulse pressure. Peripheral vascular 
resistance index was calculated as mean arterial pressure minus mean right atrial 
pressure, divided by cardiac index. Statistical significance was taken as P <0.05. 
Based on power calculations derived from previous studies [Japp et al 2010] and a 
significance level of 5%, the sample sizes (n=12) will give 90% power of detecting 
the clinically meaningful differences of 0.6 L/min in cardiac output. We have 
previously described the influence of a range of factors on regional and systemic 
vascular beds using sample sizes of 8 to 12 subjects. (Japp et al 2008, Japp et al 2010 





6.4.1   SAFETY OF PROLONGED (PYR1)APELIN-13 INFUSIONS 
No serious adverse effects occurred during prolonged infusion in either the healthy 
volunteers or in patients with chronic stable heart failure. No arrhythmias were recorded 
in either cohort. Two studies were stopped prematurely in the heart failure group, one 
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due to a pre-existing chronic back problem and the other due to uncontrolled 
hypertension, which was long-standing.  
 
6.4.2   PROLONGED (PYR1)APELIN-13 INFUSIONS IN HEALTHY VOLUNTEERS 
Systemic APLNR agonism was assessed with (Pyr1)apelin-13 (Genscript). Baseline 
haemodynamics are presented in Table 6.1. Compared to the placebo, (Pyr1)apelin-13 
caused an increase in cardiac index during the first hour (ANOVA; P <0.0001), 
which was sustained throughout the 6-hour infusion (ANOVA; P <0.0001).  There  
was   an apparent   increase in  heart rate  during  the  first   hour (ANOVA; P=0.11), 
which became statistically significant during the remaining 5 hours of infusion 
(ANOVA; P=0.0002). Peripheral vascular resistance index was reduced during the 
first hour of infusion (ANOVA; P <0.0001) but not sustained to the end of the 
infusion (ANOVA; P=0.12). Mean arterial pressure was unchanged throughout the 
(Pyr1)apelin-13 infusion (Figure 6.2)  
 
TABLE  6.1   Baseline haemodynamic data 
    (Pyr1)apelin-13  Placebo 
Cardiac Index                                     
L/min/m2 4.4±0.3 4.4±0.3 
Heart Rate                                                
beats/min 61.8±2,8 59.7±2.5 
Systolic Blood Pressure                          
mmHg 123.1±1.7 126.8±2.5 
Diastolic Blood Pressure                         
mmHg 74.5±1.4 77.4±2.2 
Mean Arterial Pressure                          
mmHg 90.7±1.3 92.1±1.2 
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Peripheral Vascular Resistance Index   


























Figure 6.2.   Percentage change in cardiac index, mean arterial pressure, peripheral vascular 
resistance index and heart rate during systemic infusion of  (Pyr1)apelin-13 (blue circles, closed) or 
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saline (black circles, open). *P <0.05, **P <0.01, ***P <0.001. One-way ANOVA with a post-hoc 
Bonferroni test. 	ANOVA - analysis of variance.	
 
 
6.4.3   PATIENTS WITH CHRONIC STABLE HEART FAILURE 
Systemic APLNR agonism was assessed with (Pyr1)apelin-13 (Genscript). Patient 
characteristics and baseline haemodynamic data are presented in Tables 6.2 and 
Table 6.3, respectively. Intravenous (Pyr1)apelin-13 infusion increased cardiac index 
during the first hour (ANOVA; P=0.003), and this was sustained throughout the 6-
hour infusion (ANOVA; P=0.0003). Both mean arterial pressure and the peripheral 
vascular resistance index were reduced during the initial hour of infusion (ANOVA; 
P=0.008 and P=0.0001, respectively), and this was maintained during the 6-hour 
infusion (ANOVA; P=0.007 and P=0.002, respectively). There was an apparent 
trend for an increase in heart rate during the first hour of infusion (ANOVA; 
P=0.051), although this did not persist or reach statistical significance during the 6-
hour infusion (ANOVA; P=0.42: Figure 6.3). Fractional shortening and left 
ventricular ejection fraction were increased following apelin infusion (ANOVA; 















TABLE 6.2   Baseline characteristics of patients with chronic heart failure 
 
                                          Baseline Characteristics 
 
Age (Yrs) 64±3 
Sex (Male/Female) 8/4 
Aetiology (Ischaemic/Idiopathic) 8/4 
NYHA II/III/IV 7⁄ 5/0 
Left Ventricular Function Severe (Ejection Fraction <20%) 9/12 




Echocardiographic Measures*   
Left Ventricular End-diastolic         
Diameter (cm) 
  6.3±0.3 
 




Fractional Shortening (%)   13±0.2 
Left Ventricular Ejection Fraction   19±2% 
Concomitant Therapy   






Aldosterone Receptor Antagonist   5/12 
Implanted Cardio-defibrillator   5/12 






TABLE  6.3   Baseline haemodynamic data	
	
 
          (Pyr
1)apelin-13  Placebo 
Cardiac Index                                     
L/min/m2 2.9±0.2 3.0±.03 
Heart Rate                                                
beats/min 61.3±4.2 58.1±3.0 
Systolic Blood Pressure                          
mmHg 128.2±7.4 126.2±6.3 
Diastolic Blood Pressure                         
mmHg 75.5±3.9 72.1±2.8 
Mean Arterial Pressure                          
mmHg 93.4±4.1 85.5±4.3 




Left Ventricular End-diastolic Diameter 
(cm) 
 
     6.3±0.3 6.3±0.3 
Left Ventricular End-systolic Diameter 
(cm) 
5.8±0.3 5.6±0.3 
Fractional Shortening (%) 10±1  13±1 
Left Ventricular Ejection Fraction (%)       21±3 25±2 
  
Aspirin   11/12 
Statin   6/12 
Loop Diuretic Therapy   4/12 
























Figure 6.3.  Percentage change in cardiac index, mean arterial pressure, peripheral vascular resistance 
index and heart rate during systemic infusion of  (Pyr1)apelin-13 (red circles, closed) or saline (black 
circles, open). *P <0.05, **P <0.01, ***P <0.001. One-way ANOVA with a post-hoc Bonferroni test. 
































































































































































Figure 6.4.  Absolute change in left ventricular end-systolic (cm), end-diastolic measurements (cm), 
fractional shortening and ejection fraction (absolute percentage change) during systemic infusion of  
(Pyr1)apelin-13 (black circles, closed) or saline (black circles open). *P <0.05, **P <0.01, 
***P <0.001. Two-way ANOVA with a post-hoc Bonferroni test. 
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This is the first study to assess prolonged systemic (Pyr1)apelin-13 infusion in man. In 
both healthy volunteers and patients with chronic stable heart failure, the effects on the 
cardiac index were sustained during infusion. No serious adverse events were observed 
during this study. 
 
6.5.1   SAFETY 
Throughout all the studies, (Pyr1)apelin-13 infusion was well tolerated. Two studies were 
stopped prematurely in patients with heart failure: one due to an episode of long-
standing chronic backache and the other one due to uncontrolled hypertension, which 
was pre-existing and controlled with medical therapy. It is important to note that no 
cardiovascular symptoms were reported in either of these studies. Additionally, no 
arrhythmias were recorded. Whilst no clinical studies have identified (Pyr1)apelin-13 to 
be proarrhythmic [Japp et al 2008; Japp et al 2010], one preclinical study recorded 
various degrees of atrioventricular node blockage in response to apelin infusion    
[Charles et al 2006]. Reassuringly, (Pyr1)apelin-13 infusion throughout this study did 
not provoke arrhythmias in healthy volunteers or in patients with chronic stable heart 
failure. The present study provides valuable information regarding the safety profile of 






6.5.2   EFFICACY 
In both healthy volunteers and patients with chronic stable heart failure, systemic 
(Pyr1)apelin-13 infusion is safe and results in sustained increased cardiac output, with no 
evidence of tachyphylaxis. The magnitude of effect of  (Pyr1)apelin-13 infusion in this 
trial is similar to previously reported studies [Japp et al 2010]. In patients with chronic 
stable heart failure we report improvements in left ventricular dimensions, which is in 
keeping with increased cardiac output. 
 
A major concern of targeting the APLNR is the potential for tachyphylaxis: a reducing 
response to continued dosing. In man, the local vascular and systemic cardiovascular 
responses to APLNR agonism demonstrate a rapid plateau in the dose response curve, as 
presented in this thesis and in keeping with previously published data [Japp et al 2008; 
Japp et al 2010]. This may represent tachyphylaxis and have serious implications for the 
therapeutic use of (Pyr1)apelin-13. Furthermore, concerns exist regarding the rapid 
internalisation of the APLNR [Messari et al 2004], which localises to a perinuclear 
cellular location once activated. Whilst preclinical data are limited, ventricular APLNR 
expression is reduced in dilated cardiomyopathy, and this may reduce the capacity of 
APLNR signalling for this type of heart failure [Földes et al 2003; Pitkin et al 2010]. 
However, varying results are reported in patients with heart failure secondary to the 
ischaemic heart disease, with both reduced [Pitkin et al 2010] and preserved ventricular 
expression patterns reported [Földes et al 2003]. From the data in the present study the 
effect of systemic (Pyr1)apelin-13 was not reduced in chronic stable heart failure, 
suggesting that there is sufficient receptor density to target. The majority of patients 
recruited to this study had ischaemic heart failure, which may be an important factor in 
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the response, although patients with dilated cardiomyopathy had a similar profile of 
response. 
 
The exact mechanism underlying the increased cardiac index is difficult to ascertain 
from this study. In preclinical studies, using a range of preclinical models from isolated 
myocytes to whole animal studies [Berry et al 2004; Dai et al 2006; Farkasfalvi et al 
2007], apelin has been demonstrated to be a potent positive inotrope. In keeping with 
this, invasive haemodynamic preclinical studies have shown a direct effect on the 
myocardium [Ashley et al 2005]. Nevertheless, as evidenced in peripheral arterial 
studies and systemic infusions, apelin functions as a vasodilator. In both protocols a 
reduction in afterload was evident throughout the first hour of (Pyr1)apelin-13 infusion. 
The response differed between healthy volunteers and patients with chronic stable heart 
failure, with the healthy cohort showing an increase in the cardiac index, without a 
sustained reduction in mean arterial pressure. In patients with chronic stable heart failure, 
(Pyr1)apelin-13 infusion resulted in reduced afterload compared to the placebo 
throughout the duration of infusion. It is likely that reduced afterload contributes to 
increased cardiac output, but the reduction in afterload was modest relative to the 
increase in the cardiac index, thus suggesting that there is a direct effect on the 
myocardium.  
 
We have studied two different populations in this protocol. The healthy volunteers were 
younger (21.1±0 yrs) and all male, compared to the chronic heart failure cohort (mean 
age 64±3 yrs), with both males and females studied. We have seen similar cardiovascular 
responses on each group, although no tachycardia was recorded in the patient group, in 
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either the first hour or during the 6-hour analysis. This is likely to reflect concurrent 
treatment with β-blockers and digoxin.  
 
We have addressed potential concerns surrounding APLNR signalling in heart failure 
and failed to demonstrate evidence of tachyphylaxis over the timescale investigated. The 
duration of infusion in these studies was 6 hours, compared to previous studies in 
humans that have been limited to 15-minute infusions [Japp et al 2008; Japp et al 
2010]. Nonetheless, this still reflects a relatively short infusion, and if the APLNR is to 
develop as a therapeutic target in chronic heart failure, data are required to assess a 
longer APLNR agonism duration. Whilst no arrhythmias were recorded in these studies, 
careful consideration and monitoring would be necessary should the APLNR be a target 
in heart failure. Studies of inotropes in heart failure have reported hazardous effects, and 
it is conceivable that chronic stimulation of the myocardium will be proarrhythmic and 
harmful [Miller et al 2008].  
 
Beyond the haemodynamic benefits that we have demonstrated, some chronic effects 
may also be beneficial. In the earlier chapters we established that there is no 
haemodynamic interaction between the apelin-APLNR and renin-angiotensin system, 
although preclinical data have shown that these two systems do in fact interact. In 
preclinical models, apelin inhibits angiotensin II-mediated cardiac fibrosis [Siddiquee et 
al 2011], and this property would be very attractive in the treatment of ventricular 
dysfunction. Investigating any beneficial effects of APLNR agonism beyond 
haemodynamic properties, such as ventricular remodelling seen in patients treated with 
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ACE inhibitors [Konstam et al 1992] or β-blocker therapies [Doughty et al 2004], 
would require chronic dosing. 
 
All of the patients investigated were receiving current evidence-based therapies in heart 
failure, with over 90% receiving some form of renin-angiotensin inhibition. The 
contribution of these agents to APLNR agonism would be interesting to study. However, 
it would not be ethical to withhold treatment of medications that improve mortality, in 
order to assess their contribution to (Pyr1)apelin-13 efficacy. Furthermore, this may 
result in decompensating their heart failure, which again would not be ethical. 
 
Whilst an oral preparation may not be available at present, the duration of infusion in 
this study may be suitable for the treatment of acute heart failure. Nevertheless, in recent 
times many drugs have had favourable haemodynamic and neuroendocrine profiles 
[Colucci et al 2000; Publication Committee for the VMAC Investigators 2002; Silver 
et al 2002; Gheorghiade et al 2004; Konstam et al 2007], although these have not 
been associated with improved outcomes. Acute heart failure represents a heterogeneous 
patient group with regard to the aetiology of ventricular dysfunction and 
decompensation, with a long, maladaptive and compensatory response duration. A brief 
infusion of any drug is therefore unlikely to improve long term outcomes.  
 
6.5.3   LIMITATIONS 
The healthy volunteer population is not representative of the population at large; the 
cohort investigated in these studies was young and exclusively male. Extrapolating these 
findings to the wider population may not be relevant. Nonetheless, the heart failure 
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population investigated is representative of a typical patient population with respect to 
aetiology, demographics and current therapy. 
 
In this present study we used thoracic electrical bioimpedance to assess cardiac output, 
and echocardiography to assess left ventricular dimensions. Whilst good correlation 
exists between invasive techniques [Shoemaker et al 1994; Suttner et al 2006; Gujjar 
et al 2008; McDonagh et al 2009], the level of agreement is not always acceptable in 
all studies [Leslie et al 2004]. The optimal technique employed to ascertain myocardial 
effects would be to undertake pressure-volume loop studies that give information 
regarding cardiac function independent of loading. However, it is ethically challenging 
to use invasive techniques to assess cardiac output over a 6-hour period, and it is not 
routinely or readily available in many centres. 
 
Whilst echocardiography data are in concordant with the haemodynamic effects seen 
with thoracic impedance cardiography assessment of the left ventricle was limit to 
one plane and not possible in all individuals studied. In order to preserve thoracic 
impedance cardiography traces, patients we requested to remain still throughout the 
measuring period and therefore assessment from any other axis was not possible. 
Moreover, there is no reliable technique to ensure measurements are obtained from 
the same position of the myocardial wall during each sample.  
 
Given that values obtained for baseline fractional shortening are low in heart failure 
cohort recruited, to small changes in left ventricular dimensions will be sensitive to 
small changes in dimension. This effect will be amplified when using the Teichholz 
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method, which cubes left ventricular dimensions, and makes assumptions regarding 
left ventricular geometry. Teichholtz method has been reported to overestimate 
ejection fraction, with a higher coefficient a variability in heart disease compared to 
healthy individuals (14.8% vs 5.1%) [Wandt et al 1999] Alternative 
echocardiographic methods could have been used to assess ejection fraction, such as 
Simpson’s biplane method, to produce a more precise assessment of ejection fraction. 
The use of echocardiogram contrast agents would have improved endocardial 
definition and may have permitted inclusion of more patients. Alternatively, other 
modalities such as magnetic resonance imaging would provide more accurate 
assessments of intracardiac volumes [Bellenger et al 2000]. Overall 
echocardiographic data support the findings presented within this study, however 
should be interpreted with caution given the know limitations of the techniques used, 
and serve to guide further investigation if the effect on APLNR stimulation on 
ejection fraction is to be determined. 
 
At present there is no acceptable method to measure plasma apelin concentration and 
none of the commercially available assays is able to detect (Pyr1)apelin-13, which is the 
most potent fragment and is abundant in cardiac tissue, and therefore the peptide of most 
interest. We have consequently been unable to assess plasma concentrations as a result of 
(Pyr1)apelin-13 infusion in this study, which would have been helpful in understanding 





6.5.4   SUMMARY  
This protocol provides essential data to guide future work in assessing the role of 
exogenous apelin in man. There are limited data in this respect, with infusions restricted 
to around 15 minutes, but this protocol provides novel information regarding the more 
prolonged cardiovascular effects of apelin in man. It is encouraging to note that the 
effects persist in patients with heart failure and are not restricted solely to healthy 
volunteers. We predict that APLNR agonism will retain efficacy and is a valid 












CHAPTER  7 
 
INVESTIGATING THE EFFECT OF EXOGENOUS (PYR1)APELIN-13  


















7.1 SUMMARY  
 
Introduction   In preclinical studies, rodents deficient in apelin have reduced 
exercise tolerance suggesting an important role for the apelin-APLNR system in 
exercise physiology.  
 
There are no clinical data assessing either the effect of apelin on exercise or the 
dynamic response of plasma apelin during exercise. The aim of this study was 
therefore to assess the effect of exogenous apelin infusion during exercise and the 
effect of exercise on plasma apelin concentration.  
 
Methods   Twelve healthy volunteers attended three cardiopulmonary exercise tests. 
On the first visit, an incremental protocol was undertaken to ascertain VO2MAX, and 
endurance protocols were performed on subsequent visits during (Pyr1)apelin-13 30 
nanomol/min or saline infusion, administered in a double blinded randomised 
crossover design. Electrocardiograph recordings, endurance time, oxygen pulse heart 
rate and blood pressure were recorded throughout with an ergometer, metabolic cart 
and semi-automated sphygmomanometer respectively. Blood samples were drawn at 
baseline and during peak exercise.  
 
Results   No adverse events were recorded during this study. Exogenous 
(Pyr1)apelin-13 infusion had no effect on endurance performance. However, there 
was an increase in plasma apelin concentration in response to exercise.  
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Conclusion   This is the first study in man to assess the (Pyr1)apelin-13 infusion 
during exercise. Exogenous apelin infusion had no effect on endurance times, 
however an increase in plasma apelin concentration was observed. These data 
suggest endogenous APLNR activation does not improved exercise performance in 
healthy individuals. Assessing the effect of exogenous apelin in patients with heart 
failure, who have reductions in plasma apelin, merits investigation as this cohort may 




The apelin-APLNR system is implicated in having a significant role in 
cardiovascular regulation. Its primary actions in the circulatory system are to mediate 
positive inotropism [Szokodi et al 2002; Berry et al 2004; Farkasfalvi et al 2007; 
Japp et al 2010] and vasodilatation [Lee et al 2000; Japp et al 2008; Japp et al 2010]. 
 
Apelin is the most potent inotrope identified and is effective at subnanomolar 
concentrations [Szokodi et al 2002], as investigated in many preclinical models, 
ranging from isolated myocytes to whole animal models. In humans, exogenous 
apelin has been shown to increase cardiac output in both healthy volunteers and 
patients with chronic stable heart failure [Japp et al 2010]. 
 
Whilst the inotropic action of the apelin-APLNR system has been well described 
under resting conditions, there are limited data on the contribution of this system to 
	 150	
exercise performance. Studies assessing the contribution of the apelin-APLNR 
system during exercise are limited to knockout models. In rodent models deficient in 
either APLNR or apelin, deficiencies in exercise performance are observed. VO2MAX  
is reduced in apelin-deficient mice [Charo et al 2009], suggesting that the apelin-
APLNR system contributes to ventricular performance in exercise.  
 
Plasma apelin concentrations have been reported in healthy individuals and a range 
of diseases. There is general agreement that plasma apelin concentrations are reduced 
in heart failure [Chen et al 2003; Földes et al 2003; Chong et al 2006;             
Francia et al 2007] and a causal role is implied. In less severe heart failure an 
increase in plasma is reported, signifying an initial adaptive attempt to augment 
myocardial contraction, which is greatly reduced in severe heart failure               
[Chen et al 2003]. Studies in man profiling apelin-APLNR expression responses, in 
response to ventricular or biventricular pacemaker insertion, show increases in 
apelin-APLNR as ventricular function improves [Chen et al 2003;                    
Francia et al 2007]. It is conceivable that exogenous apelin given to these patients 
groups may translate into a functional benefit. There are no data profiling plasma 
apelin in response to exercise or the effects of exogenous apelin during exercise.  
 
The aims of this protocol were to assess the safety and efficacy of exogenous apelin 
during exercise, primarily to investigate the ergogenic effect of apelin infusion and to 




7.2.1   HYPOTHESIS  
Exogenous (Pyr1)apelin-13 will increase endurance time and plasma apelin 




Twelve healthy volunteers attended on three occasions, with each visit separated by 
one week, for cardiopulmonary exercise testing. One dataset was withdrawn prior to 
unblinding, due to submaximal exertion attributed to a chest infection that was not 
disclosed prior to the study visit. All studies were performed in a quiet, 
temperature controlled room maintained at 22-24°C. On the first visit, the subjects 
performed a ramp incremental symptom-limited endurance protocol, in order to 
ascertain maximal workload. Subjects initially sat resting on the ergometer for 
2 minutes and thereafter pedalled for 1 minute with no load applied. Workload was 
then increased incrementally and the test continued until symptoms limited further 
effort. Encouragement was given throughout the tests to maximise the subjects’ 
exertion. From visit, the maximal work-load each participant was capable of was 
recorded. Subsequently, participants attended visits for two further visits that were 
endurance protocols (Figure 7.1), in which the workload was set at 80% of the 
maximal, as previously reported [Greer et al 2000; Oga et al 2003; Vagaggini et al 
2011]. 2 minutes of rest were followed by 1 minute of unloaded cycling prior to the 
endurance exercise tests. Breath-by-breath analysis was recorded throughout, and 




















(Pyr1)apelin-13 30 nmol/min or saline 
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Figure 7.1  Study protocol. A) Visit 1: Maximal effort incremental cardiopulmonary exercise test. 


















In a crossover design subjects were randomised in a double blinded fashion to 
receive a (Pyr1)apelin-13 (30 nmol/min) (Clinalfa AG, Läufelfingen, Switzerland) 
infusion or a matched saline placebo infusion through a peripheral cannula at 
1 mL/min during endurance exercise testing. Blood pressure, heart rate, gas 
exchange and electrocardiogram were recorded throughout the protocol. Blood 
samples were drawn at baseline and at peak exercise and recovery from the non-
infused arm during endurance exercise testing. Prior to undertaking exercise testing, 
spirometry was performed. 
 
7.3.1  PLASMA APELIN  
Plasma apelin was assayed using standard, commercially available ELISA assay and 
processed in accordance with the manufacturer’s instructions. Briefly, bloods were 
drawn into EDTA vacutainers, centrifuged at 4oC, 1500 rpm for 20 minutes and 
stored at -80oC. A protein extraction phase was undertaken (C18 extraction column, 
Phoenix Peptides) and ELISA performed thereafter. Plasma apelin concentrations 
were assessed during the placebo visit, as the current assay does not detect the 
pyroglutamated form of apelin-13. 
 
7.3.2   DATA AND STATISTICAL ANALYSIS 
Endurance time, mean arterial pressure, oxygen pulse, ventilation efficiency and 
heart rate during (Pyr1)apelin-13 infusion were compared with those during the 
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placebo infusion. Plasma apelin concentration at baseline and peak exercise was 
assessed from the placebo visit. All were analysed by paired two-tailed Student’s t-
test using GraphPad Prism. Statistical significance was taken as P <0.05. Based on 
previous studies investigating cardiopulmonary exercise testing we calculated that to 
see a 20% effect on exercise performance we will need a sample size of 12 at 90% 





7.4.1   INCREMENTAL EXERCISE TESTING 
APLNR agonism was assess with (Pyr1)apelin-13 (30 nmol/min) (Clinalfa). Baseline 
characteristics and workloads during incremental testing are presented in Table 7.1. 
Subjects were young males with moderate exercise ability. One data set was 
withdrawn prior to analysis as the participant had coryzal symptoms on the last visit, 
we therefore present data for 11 participants. Incremental exercise test effort was 
satisfactory, with respiratory exchange ratio  >1.0 accepted as supramaximal effort. 
 
7.4.2   SAFETY  
All studies were well tolerated, with no adverse events. In particular, no 
cardiovascular symptoms were reported during either endurance exercise test, and no 













TABLE 7.1   Baseline characteristics of the participants 
 
Baseline Characteristics 
Age (yrs) 29±3 
Weight (kg) 78±3 
Height (m) 1.8±0.0 
BMI (kg/m2) 24.6±0.5 
Forced Expiratory Volume (L) 5.0±0.3 
Forced Vital Capacity (L) 6.3±0.3 
VO2MAX (mL/min/kg) 46.0±3.0 
Incremental Work (W) 303.0±24.5 






















Figure 7.2.  Endurance time during (Pyr1)apelin-13 infusion (blue) or saline (red). Paired Student’s t-test 
(P=ns).  
ET - endurance time; ns - not significant. 
 








7.4.3   EFFICACY 
Intravenous (Pyr1)apelin-13 was not associated with increased endurance time     
(563s versus 552s; paired Student’s t-test, P=ns). No differences in heart rate or mean 
arterial pressure were detected throughout endurance testing, however oxygen pulse was 
reduced during (Pyr1)apelin-13 infusion (paired Student’s t-test, P=ns). (Pyr1)apelin-13 
infusion reduced oxygen pulse during exercise (23.1±1.2 mL/kg versus 21.7±1.1 mL/kg; 
paired Student’s t-test, P=0.0015), while the respiratory exchange ratio was similar 
during each endurance test and the values obtained throughout are consistent with 





TABLE 7.2   Haemodynamic parameters at peak exercise during placebo or 
(Pyr1)apelin-13 visits   
 
                       Placebo       (Pyr1)apelin-13 
Respiratory Exchange Ratio 1.1±0.0 1.1±0.0 
Oxygen Pulse                                          
(mL/beat) 23.1±1.3 21.7±1.1* 
Heart Rate at Maximal Exertion               
(bpm) 170±5 174±4 
Mean Arterial Pressure at Maximal Exertion 
(mmHg) 111±4 117±4 
Endurance Time                                                
(s) 551.8±65.9 562.8±61.4 
Paired Student’s  t-test. *P <0.05, **P <0.01, ***P <0.001. 
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7.4.4  PLASMA APELIN CONCENTRATION 
Paired baseline and exercise sample were available for 8 participants. Plasma apelin 
concentrations were increased in response to exercise. Baseline plasma apelin 
concentrations were 0.17±0.06 ng/mL rising to 0.26±0.1 ng/mL at peak exercise 

















Figure 7.3.  Baseline plasma apelin concentration (red), peak exercise apelin concentration (blue). 





























7.5       DISCUSSION 
 
This is the first study in man to assess the effects of exogenous (Pyr1)apelin-13 
infusion during exercise. We can report that no effect on endurance time, heart rate or 
mean arterial pressure during exercise was observed in this study.  
 
Under rest conditions, APLNR agonism consistently mediates positive inotropic effects, 
observed in both preclinical and clinical studies, in both healthy and failing myocardium. 
However, there is a paucity of data assessing the contribution of the apelin-APLNR 
system to exercise. Animal models, deficient in either apelin or APLNR, have been 
shown to have reductions in basal cardiac contractile indices [Charo et al 2009] that 
functionally translate to a reduced exercise capacity. Furthermore, apelin-deficient 
rodents rapidly develop heart failure in response to an increased afterload, which is in 
keeping with a requirement of this system to function under conditions of stress       
[Kuba et al 200]), although this may reflect a chronic rather than an acute effect. In this 
study, we have failed to demonstrate any effect of exogenous apelin in healthy 
individuals exercising at high workloads, suggesting that under these conditions 
exogenous APLNR stimulation is not ergogenic.  
 
The (Pyr1)apelin-13 dose infused in this study was in line with other clinical studies 
[Japp 2010] and sufficient to activate the APLNR; therefore, we do not believe that any 
lack of effect results can be attributed to inadequate dosing. These concentrations have 
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been shown as effective doses in both the acute and subacute settings in increasing 
cardiac output and reducing mean arterial pressure. 
 
Endurance protocols set at 80% of VO2MAX, with similar dosing protocols, have been 
used in both healthy volunteers [Graham and Spriet 1995; Greer et al 2000] and patient 
groups [O'Donnell and Lam 1998; Oga et al 2003; O’Donnell 2006; Salcedo et al 
2007; Guenette et al 2011; Vagaggini et al 2011] and been able to detect changes in 
endurance times. In trained athletes caffeine supplementation prior to exercise extends 
endurance time, while in chronic obstructive airways disease, acute bronchodilator 
therapy increased endurance time by around half a minute. We do not believe the lack of 
effect was therefore related to selecting an inappropriate workload, as adequate stress 
levels were selected in this protocol. Furthermore, these studies employed acute dosing 
techniques, similar to those in this study, and were able to detect treatment effects. Thus, 
in populations that were trained more and trained less, a similar study design has been 
able to detect changes in endurance. However there may have been subtle effects of 
APLNR agonism on exercise capacity this study was not powered adequately to detect. 
 
APLNR activation has no clear dose response relationship, with the effects plateauing 
rapidly [Japp et al 2008; Japp et al 2010]. It is possible that exercise releases 
endogenous stores of apelin that saturate the available APLNR, resulting in no additional 
exogenous apelin effect. We report results from a healthy cohort, and it is conceivable 
that in disease populations the effects of exogenous apelin may differ. 
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There may have been off-target effects from exogenous apelin infusion. Oxygen pulse, 
determined by stroke volume, reduced during (Pyr1)apelin-13 infusion and exercise. No 
difference in heart rate or afterload was noted between the two endurance visits, which 
would suggest that the observed difference was explained by either contractility or 
preload. Given that all studies investigating the effect of the apelin-APLNR system on 
myocardial contractility reported positive inotrope effects, a reduction in preload may be 
the most plausible explanation. This may be explained by vasodilatation in vascular beds 
that would normally be constricted. No assessment of blood flow through vascular beds 
was made during this protocol, but it is possible that APLNR agonism mediated atypical 
volumes in redistribution during exercise.  
 
An increase in plasma apelin was detected, suggesting that this endogenous hormone 
may have a role in healthy exercise physiology. Alternatively, exercise may be a 
stimulus for apelin production, rather than actively increasing cardiac output. 
However, given data from preclinical studies, and the data presented in this thesis, it 
is reasonable to propose a role for apelin in exercise physiology. There are concerns 
regarding the assay that is currently available, and there is no cross-reactivity with 
pyroglutamated apelin. Considering that (Pyr1)apelin-13 is the most abundant 
isoform of apelin in cardiac tissue and is recognised to be the most potent isoform, 
understanding its contribution to exercise is essential. This cohort is a healthy well-
trained population, so whether or not these dynamic changes are similar in disease 






7.5.1   LIMITATIONS 
This is the first study infusing apelin during exercise and has correctly been 
performed in a small number of healthy volunteers. These data may not be 
informative with respect to patient studies.  
 
We tested endurance at one level, which is in keeping with reported literature 
[Graham and Spriet 1995; Greer et al 2000]. However it may have been more 
informative to test individuals over a range on endurance workloads and assess the effect 
of exogenous apelin at even more extreme workload. This would have resulted in 
increasing the number of visits and may have introduced both training and learning 
effects.  
 
We present data showing a rise in plasma apelin during exercise. However, there are 
concerns regarding the accuracy of this assay and caution is required. Furthermore 
we were only able to analyse a limited number of paired samples owing to difficulty 
in sampling some individuals during exercise. Given that the cardiac atria are 
suggested to be a major source of circulating apelin, arterial samples may be more 
informative regarding plasma apelin concentration during exercise, we have 
collected venous samples as this negates the need for invasive arterial cannulation. 
 
There are no APLNR antagonists available at present, however this would be 
beneficial in understanding the role of the apelin-APLNR system in exercise. We 
	 164	
propose that endogenous APLNR contributes to exercise, but cannot be augmented 
with exogenous (Pyr1)apelin-13, treatment with and antagonist would result in a 
reduction in exercise performance. 
 
7.5.2   CONCLUSIONS 
Exogenous (Pyr1)apelin-13 infusion during cardiopulmonary exercise testing 
progressed with no adverse effects, and in particular we did not detect any 
arrhythmias. Exogenous (Pyr1)apelin-13 had no effect on exercise duration in this 
study. However, this study protocol was restricted to healthy volunteers and it is 











CHAPTER  8 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
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8.1 SUMMARY OF THE FINDINGS  
 
The role of the apelin-APLNR system in cardiovascular health and disease is 
becoming increasingly better defined. Apelin receptor activation mediates arterial 
and venous vasodilatation which is predominantly endothelial and nitric oxide-
dependent [Lee et al 2000; Tatemoto et al 2001; Ishida et al 2004; Japp et al 2008], 
whilst it is also reported as the most potent inotrope in vitro [Szokodi et al 2002]. In 
a range of preclinical and clinical studies this effect has been consistently 
demonstrated, and in vivo in humans this effect persists, albeit with reduced potency 
[Japp et al 2010]. 
 
The APLNR is a G protein-coupled receptor that is most closely related to the AT1R 
[O'Dowd et al 1993]. Each of these receptors is located in similar locations 
throughout the body, but their cardiovascular actions are largely opposed [Ashley et 
al 2006]. In addition to opposing actions on vascular tone [Gurzu et al 2006], 
inflammation [Chun et al 2008] and fluid balance [Hus-Citharel et al 2008], there 
appears to be a direct interaction between the APLNR and AT1R. The inhibition of 
AT1R expression results in an increase in APLNR expression and a reduction in 
mean arterial pressure in a hypertensive rodent model, whilst elevated angiotensin II 
reduces cardiac apelin expression [Iwanaga et al 2006]. Furthermore, preclinical data 
suggest that there is a direct interaction between each of these receptors and they are 
able to form heterodimers, which in turn impacts on intracellular signalling [Chun et 
al 2008; Sun et al 2011]. APLNR stimulation inhibits renin-angiotensin signalling 
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and has been shown in preclinical studies to reduce angiotensin II cardiac fibrosis 
[Siddiquee et al 2011]. 
 
Renin-angiotensin activation is deleterious to health in a range of diseases, but this is 
particularly true of cardiovascular disease and heart failure. Pharmacological 
inhibition results in reduced mortality [Cleland et al 1997; Swedberg et al 1999], and 
importantly, added survival benefits are seen in patients treated with more than one 
class of renin-angiotensin medication [McKelvie et al 1999; Pfeffer et al 2003; 
Young et al 2004].  
 
The potential of the apelin-APLNR system may be 2-fold; firstly it can improve 
myocardial performance and secondly it may antagonise the renin-angiotensin 
system.  
 
8.1.1   SUBACUTE RENIN-ANGIOTENSIN DOES NOT ALTER THE LOCAL OR SYSTEMIC 
CARDIOVASCULAR ACTIONS OF (PYR1)APELIN-13 
In a randomised single blinded crossover study, 12 healthy volunteers were assigned 
to a salt-restricted (<12 mmol Na+ with a single dose of furosemide) or a normal diet. 
In this study there was good adherence to the sodium deplete diet and significant 
increases in renin-angiotensin system activation were achieved. The local and 
systemic cardiovascular actions of (Pyr1)apelin 13 were unaffected by subacute 
renin-angiotensin activation. We predict that (Pyr1)apelin 13 will retain efficacy in 
the presence of prolonged renin-angiotensin activation. 
 
	 168	
8.1.2   ACUTE ANGIOTENSIN II DOES NOT ALTER THE LOCAL SYSTEMIC 
CARDIOVASCULAR ACTIONS OF (PYR1)APELIN-13 
Thereafter, in order to assess any immediate interaction between the apelin-APLNR 
and renin-angiotensin systems, we performed a randomised double blinded crossover 
study, recruiting 12 healthy volunteers, and administered angiotensin II or placebo 
infusion. Local intrabrachial arterial angiotensin II infusion was titrated to a reduced 
forearm blood flow by 50%, and in the systemic studies a subpressor angiotensin II 
dose was administered. In both local and systemic acute angiotensin II infusion the 
cardiovascular actions of apelin persisted. Preclinical data point to the formation of 
heterodimers between the APLNR and AT1R which alters signal transduction from 
their respective ligands. In this study we have not been able to demonstrate any acute 
interaction between the apelin-APLNR and renin-angiotensin systems. 
 
8.1.3   INVESTIGATING THE CARDIOVASCULAR EFFECTS OF (PYR1)APELIN-13 IN 
CHRONIC STABLE HEART FAILURE 
Given the downregulation of myocardial APLNR expression and the reduction in 
circulating plasma apelin, in heart failure, the effect of exogenous apelin infusion 
was assessed. Whilst brief, the concerns regarding safety and efficacy were 
addressed during this study. Eight patients with chronic stable heart failure were 
investigated in a randomised double blind crossover design. Systemic infusion of 
(Pyr)apelin-13 increased cardiac output and there was a concomitant reduction in 
afterload. During these studies no serious adverse events were reported, and it is 
noteworthy that no arrhythmias were recorded. However, a rapid plateau was evident 
in response to ascending doses, thus suggesting tachyphylaxis. Additionally, this 
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may also represent reduced myocardial APLNR density and a system that is readily 
exhausted. 
 
8.1.4   INVESTIGATING THE CARDIOVASCULAR EFFECTS OF PROLONGED 
(PYR1)APELIN-13 INFUSION IN HEALTHY VOLUNTEERS AND PATIENTS WITH 
CHRONIC STABLE HEART FAILURE 
Given concerns over tachyphylaxis and the potential reduction of APLNR density, it 
was necessary to assess the cardiovascular response to (Pyr1)apelin-13 infusion over 
a prolonged period. In these studies we extended the duration of apelin infusion in 
humans 25-fold, therefore representing the longest duration of exogenous apelin 
infusion in vivo in humans. A randomised double blinded placebo control crossover 
study was performed in healthy volunteers and patients with chronic stable heart 
failure, with 12 participants recruited into each study. All of the infusions were 
well tolerated and no serious adverse events were recorded. As with the brief 
infusions, but of more importance given the increase in duration, no arrhythmias 
were captured. During the 6-hour infusion the effects of (Pyr1)apelin-13 persisted 
and showed no evidence of tachyphylaxis. Similar increases in the cardiac index 
were observed in both the healthy controls and the patient cohort. Throughout the 
initial hour of infusion, left ventricular dimensions were recorded in the patient 
group and improved left ventricular performance was evident. This study 
demonstrated that APLNR signalling persists over a prolonged infusion period, and 
importantly the effect persists in patients with chronic stable heart failure. 
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8.1.5 INVESTIGATING THE EFFECT OF (PYR1)APELIN-13 ON EXERCISE 
PERFORMANCE 
In this study we explore the effect of exogenous (Pyr1)apelin-13 infusion during 
exercise. Exogenous (Pyr1)apelin-13 in man is inotropic when infused under resting 
conditions and during acute and prolonged infusion, in both healthy volunteers and 
patients with chronic stable heart failure. No study has previously assessed the effect 
of APLNR stimulation during exercise. Given the proposed role in ventricular 
function, this important study addressed the contribution of exogenous       
(Pyr1)apelin-13 infusion during exercise in healthy volunteers. Eleven healthy 
volunteers performed an endurance cardiopulmonary exercise test in a random 
double blinded crossover design, following the determination of VO2MAX on 
incremental testing. Exogenous apelin had no effect on endurance times in this 
cohort. In healthy volunteers it is possible that there is no, or minimal, contribution 
of apelin or that endogenous activity cannot be supplemented. This merits further 
investigation in patients with ventricular failure, in order to assess the effect of 
targeting the APLNR during exercise. 
 
8.2 FUTURE DIRECTIONS 
 
8.2.1   CARDIOVASCULAR 
In this thesis we have presented data assessing the efficacy of the APLNR agonist in 
the context of renin-angiotensin upregulation and profiled the cardiovascular 
response to acute and prolonged apelin infusion in chronic stable heart failure. We 
conclude that apelin functions independently of angiotensin II, and the APLNR is a 
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potentially exciting therapeutic target. At present, the main barriers to exploring the 
apelin-APLNR system in heart failure are the lack of an oral compound and the fact 
that it is challenging to use prolonged infusion. Preclinical data support an 
antifibrotic role in myocardium, and in particular it abrogates angiotensin II-induced 
fibrosis [Siddiquee et al 2011]. Clearly, any beneficial effect on myocardial 
remodelling would be of great value, provided that there was an accompanied 
improvement in ventricular function that translated to a reduction in both morbidity 
and mortality. At present, there is little scope to assess these parameters in patients 
with chronic stable heart failure. 
 
Whilst we were unable to identify any interaction between the apelin-APLNR and 
renin-angiotensin systems in the studies performed, the protocols were limited to 
brief studies. That we did not see an interaction does not exclude the possibility that 
an interaction exists and APLNR agonism may inhibit the renin angiotensin system. 
In the longer term, using chronic dosing regimens, APLNR agonsim may be 
synergistic with current strategies directed at the inhibiting renin-angiotensin system, 
which may translate to an improvement in ventricular performance and survival. 
There have been significant advances in the pharmacological therapies used in 
chronic heart failure, with medication largely directed at inhibiting maladaptive 
neurohumoral responses.  
 
8.2.2   ACUTE HEART FAILURE 
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As the prevalence of chronic heart failure rises, an accompanying rise in acute heart 
failure is predicable, along with the unavoidable accompanying morbidity, mortality 
and economic burden [Cowie et al 2000].  
 
Designing appropriate studies in acute heart failure is not straightforward, and any 
study in this area will need careful consideration [McDonagh et al 2011]. Acute heart 
failure is a heterogeneous condition and may arise from decompensated, well-
established chronic heart failure through to mechanical abnormalities such as 
ruptured mitral valve chordae; pharmacological intervention in the latter would be of 
questionable benefit. Furthermore, the benefit gained from short duration 
pharmacological intervention to treat a condition that has developed over a chronic 
duration is likely to be minimal. 
 
Progress in acute heart failure has not shared the same advances in prognosis seen in 
chronic heart failure, and there has been little development with regard to new 
pharmacological agents [Konstam et al 2007; McMurray et al 2007;                  
Miller et al 2008]. Furthermore, some studies report increased mortality [Sackner-
Bernstein et al 2005] in this cohort when treated with agents that have a similar 
haemodynamic profile to apelin. One recent trial contradicts the main body of 
evidence and has reported favourable outcomes in patients presenting with acute 
heart failure treated with serelaxin [Teerlink et al 2013]. In addition to an 
improvement in initial symptoms, a signal of increased survival was observed. The 
trial was not powered to detected survival differences in each arm and this result is 
largely hypothesis generating; furthermore multiple tests were performed on these 
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data. Whilst reconciling the improved survival that result from a brief drug infusion, 
reduction in organ damage, as assessed by relevant circulating plasma biomarkers, 
was reported, which may offer some biological plausibility to the finding [Metra et al 
2013]. 
 
There may be a potential role for apelin in the treatment of patients presenting with 
hypotension and impaired ventricular function, who need supportive therapy in order 
to increase ventricular function. The current inotropic therapies are arrhythmogenic 
and associated with adverse events. Whilst the inotropic action of apelin is perhaps 
modest, there is little change in mean arterial pressure such that initiation would be 
relatively straightforward and require minimal monitoring. We have limited data 
assessing the arrhythmogenic potential of APLNR agonism, with clinical trials 
limited to small numbers. Whilst we have used an infusion duration that would be 
suitable for acute heart failure treatment, larger numbers of trials are required to 
assess fully the safety of APLNR agonism.  
 
The utility of apelin as a biomarker, in its current form, is limited. There are well-
established biomarkers for heart failure, and at present the current commercially 
available apelin assays add little with respect to diagnosis or short term prognosis 
[van Kimmenade et al 2006]. Nonetheless, it is conceivable that more precise assays 
will become available and may prove to be more informative.  
 
8.2.3 VASCULAR DISEASE 
Atheroma 
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Preclinical data show that apelin inhibits angiotensin II-induced aneurysm formation 
and limits atheroma progression [Leeper et al 2009]. This effect is mediated through 
nitric oxide and is independent of blood pressure. The data from these studies are 
taken from ApoE knockout rodent models that represent an extreme phenotype not 
receiving evidenced-based lipid-lowering medication. These effects may not be 
present in humans, and furthermore an incremental benefit on current medical 
therapy would need to be proven. Again, any studies that wish to explore this area of 
research will require an oral preparation in order to assess these chronic effects. 
 
Systemic Hypertension 
APLNR signalling may be of benefit in systemic arterial hypertension. Preclinical 
and clinical studies have shown a reduction in mean arterial pressure, and whilst 
largely modest, this may be a useful adjuvant to current therapy. Whilst the best 
clinical outcomes in hypertensive patients are observed in those that experience the 
largest reduction in blood pressure, modest reductions in blood pressure still reduce 
the risk of heart failure and strokes [Czernichow et al 2011]. 
 
Idiopathic Pulmonary Arterial Hypertension 
There are emerging data supporting a significant role for the apelin-APLNR system 
in pulmonary hypertension. Preclinical models of hypoxic- and monocrotaline-
induced pulmonary hypertension show downregulation of the apelin-APLNR system 
in pulmonary hypertension [Falão-Pires et al 2009; Chandra et al 2011]. Rodents 
deficient in apelin and exposed to hypoxia develop more severe pulmonary 
hypertension than wild types, and small pulmonary arterioles are obliterated 
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[Chandra et al 2011], therefore suggesting that the apelin-APLNR system protects 
against the development of IPAH. Interestingly, treatment with apelin prevents the 
onset of monocrotaline-induced pulmonary hypertension [Falão-Pires et al 2009]. 
There are limited clinical data in patients in this cohort; however, the apelin-APLNR 
system does appear to contribute to the disease. In patients with pulmonary arterial 
hypertension a reduction in circulating plasma apelin has been identified [Goetze et 
al 2006]. 
 
Given the inotropic action of apelin and its downregulation in pulmonary 
hypertension, there may be some therapeutic potential for this hormone system. In 
humans, the majority of data regarding apelin and ventricular dysfunction come from 
studies primarily assessing left ventricular dysfunction. Brief systemic infusions 
increase cardiac output in healthy volunteers, and this effect is preserved in patients 
with chronic stable heart failure [Japp et al 2010]. Furthermore, in studies assessing 
the prolonged infusion of (Pyr1)apelin 13, efficacy is retained and there are no 
adverse effects. The inotropic action of apelin may be critical in IPAH, as right 
ventricular function predicts patient outcomes [van de Veerdonk et al 2011]; 
consequently, the effect of APLNR agonism on cardiopulmonary performance merits 
investigation in this cohort.  
 
The precise physiological role of apelin, and hence the consequences of reduced 
plasma concentrations in IPAH, are unknown. Given the biological properties of 
apelin and the data from heart failure studies, it is likely that apelin-APLNR 
contributes to the pathophysiology of IPAH. 
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Increasingly, therapies that are effective in treating left ventricular failure are being 
investigated in patients with IPAH, as it is becoming evident that right ventricular 
function is the key predictor of survival in this cohort [de Man et al 2012]. A series 
of clinical studies has been planned to characterise the pulmonary and systemic 
cardiovascular response to apelin in pulmonary hypertension. We plan to investigate 
patients with idiopathic pulmonary arterial hypertension, pulmonary hypertension 
secondary to left heart disease and healthy control subjects. We will recruit 21 
patients for each group and the subjects will attend for invasive haemodynamic 
studies. During right heart catheterisation, the patients will receive systemic 
(Pyr1)apelin-13 infusions at 3, 10 and 30 nmol/min for 10 minutes or a placebo in a 
double blinded crossover design.  
 
We predict that apelin will increase cardiac output and reduce pulmonary arterial 
pressure, and as such the haemodynamic effects of apelin will be proven beneficial in 
pulmonary hypertension. This is the first human study designed to assess the 
vascular effect of apelin in the pulmonary circulation in vivo.  
 
We have assessed the feasibility of apelin infusion during cardiopulmonary exercise 
testing, the results of which are presented above. Our next objective is to assess the 
effect of (Pyr1)apelin-13 on exercise in patients with IPAH. We aim to recruit 
12 stable patients who have been on their current medication for at least 8 weeks and 
will attend up to three occasions at least one week apart for cardiopulmonary 
exercise testing; patients that have a baseline cardiopulmonary exercise test within 
	 177	
4 weeks of entry will not be required to undertake a baseline test. On the first visit, 
the participants will undertake a cardiopulmonary exercise by completing a ramp 
incremental exercise test to establish VO2PEAK. Thereafter, they will attend two 
further exercise tests, exercise at 80% of their maximal workload and be randomised 
in a double blinded crossover design to either (Pyr1)apelin-13 or a placebo. We 
predict that (Pyr1)apelin-13 will increase exercise ability in patients with IPAH.  
 
Perhaps idiopathic pulmonary arterial hypertension provides a unique opportunity to 
circumvent the current pharmacokinetic limitations of apelin. Some of this patient 
population are treated with intravenous therapies through indwelling Hickman lines, 
and, provided that combining these preparations in solution is safe, there is potential 
to administer apelin for long durations. In addition to the haemodynamic effects of 
apelin, this would allow for an investigation of chronic dosing and any effects of 
ventricular and vascular remodelling.  
	
8.3 CONCLUDING REMARKS 
 
 
The apelin-APLNR system is in its infancy. Further work is necessary to fully 
characterise this system and understand its role in cardiovascular physiology and 
pathophysiology. Most obviously, a reliable assay that reliably detects plasma apelin 
concentration would allow definite understanding of plasma concentrations in 
patients with cardiovascular disease. Additionally such an assay would assist in 
understanding pharmacokinetic properties of exogenous apelin, which may refine 
dosing regimes and help explain current dose response data. 
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No reliable antagonist is available. The ability to inhibit APLNR signalling would 
greatly enhance understanding the contribution of the apelin-APLNR to myocardial 
performance under basal and resting conditions.  
 
In the studies presented in this thesis we have demonstrated that the efficacy of the 
apelin-APLRN system is retained during conditions of renin-angiotensin activation. 
Furthermore in healthy and diseased myocardium there is sustained response to 
APLNR activation. Taken together these studies suggest that this system is a viable 
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